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ABSTRACT 
Nucleic acid detection is of central importance for the diagnosis and treatment of genetic 
diseases, infectious agents, bio-warfare agents, and drug discovery. Nucleic acid testing for 
diseases is exclusively performed in laboratories using high-end instrumentation and personnel. 
However, this has developed the need for point of care diagnostics which can provide near-
patient testing in a clinic, doctor’s office, or home. Such diagnostic tools can prove advantageous 
when rapid response is required or when suitable facilities are unavailable. Compared to 
equivalent methods used in laboratories, point of care testing is more affordable, as it eliminates 
the need for expensive instrumentation and skilled labor. One option involves the use of lateral 
flow assays. Pre-fabricated strips of dry reagents activated upon fluid application are already 
used in diagnostics, such as to ascertain pregnancy. Nucleic acid based detection assays on 
lateral flow offer several advantages over traditional microbiological detection methods.  
In this work we introduce a lateral flow biosensor that can combine the optical properties 
of nanoparticles (such as gold nanoparticles) with conventional immunoassay techniques to 
deliver a simple platform for rapid analysis of DNA with high sensitivity and selectivity. The 
quick 30 minute assay provides a platform to detect multiple nucleic acids with high efficiency 
achieved via chromatographic separation sandwich-type DNA hybridization reactions. Captured 
gold nanoparticles on the device can provide qualitative analysis by observing the color change 
to red and a semi-quantitative analysis via a strip reader. The biosensor was applied to the 
detection of human genomic DNA directly with high sensitivity and selectivity. The work was 
further expanded to detect Chlamydia trachomatis and Neisseria gonorrhoeae samples using 
nucleic acid amplification to generate large numbers of target copies. Improvements were made 
in the preparation of the biosensor to enable detection of Human Papilloma Virus Type-16. The 
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clinical samples obtained were amplified using PCR for direct detection on the lateral flow 
biosensor without interference from other HPV types (e.g. HPV 18). The feasibility of the 
biosensor shows great potential for further development to assure its use in point of care 
diagnosis. The promising properties of the biosensor are reported in this dissertation. 
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CHAPTER 1. INTRODUCTION 
This section provides the introduction about detection of multiple samples of nucleic 
acids on Lateral Flow Biosensors and its application on a real sample for C. Trachomatis, N. 
Gonorrhea and HPV 16 analyses, respectively. This chapter also discusses DNA-based 
biosensors, traditional and current methods to detect samples of nucleic acids, an introduction to 
sexually transmitted infections, and current methods to diagnose Chlamydia trachomatis, 
Neisseria gonorrhoeae and HPV-16. 
1.1. DNA Detection 
The fundamental basis of the detection of specific nucleic acid sequences is base pairing 
between complementary strands of DNA or RNA. However, at high temperatures (e.g. 90°C to 
100°C) the complementary strands of DNA denature or separate from each other, resulting in 
two single strands of DNA. If the denatured strands of DNA are incubated under appropriate 
conditions they can result in re-hybridization to form a double stranded molecule. This nucleic 
acid hybridization provides a platform for the detection of DNA or RNA sequences that are 
complementary to nucleic acid sequences isolated as a desired target. One of the traditional 
methods to detect specific sequences of nucleic acid was developed by Edward M. Southern in 
1970s. The technique, southern blotting, combines the transfer of DNA fragments from an 
agarose gel to a filter membrane and subsequent detection by labelled probe via hybridization. 
According to Thurmon (2014), DNA detection includes a group of procedures in which 
DNA extracted from the cells of the patient is tested in lab for changes suspected of causing a 
disease. DNA detection is also used to collect other data essential for appropriate health care. 
Assuring the accuracy of disease diagnosis is the most essential reason for DNA detection, as 
several diseases can exist in a form that is identifiable using these methods. DNA detection is 
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also important in determining liability for financial assistance and for inheritance legalities. Kuhr 
(2000) mentioned that the reliability and rapid detection of small fragments of RNA/DNA has 
become highly essential in diagnosis of molecules. 
Umek et al. (2001) stated that electrochemical technologies have revealed the critical 
importance of offering viable solutions to the challenge of detection. Individually addressable 
arrays of microelectrodes have been described for diagnosis of molecules which can be 
combined directly with microfluidics and microelectronics systems to realize benefits in 
multiplex detection and miniaturization. Additionally, Li et al. (2003) described that elements of 
nanoscale sensing can be integrated to obtain ultrahigh sensitivity. Nano-electrodes, specifically 
a carbon nanotube-based nano-electrode array, can be combined into an EC system for 
ultrasensitive detection of chemicals and DNA. Therefore, it can be inferred that DNA detection 
plays an essential role in different fields related to health care.  
1.1.1. Methods to detect DNA 
According to the BBC (2013), forensic, genetic and parental testing look for differences 
in genetic markers between two biological samples because all body cells contain similar DNA, 
so samples can be taken from anywhere on the body: including hair follicles, blood, skin and 
other fluids of the body. DNA is separated first from the cells and millions of copies are made 
using a method known as PCR (polymerase chain reaction); it utilizes a naturally existing 
enzyme to copy a particular expansion of DNA repeatedly. Having numerous copies of DNA 
makes the genetic code easier to examine.  
There are numerous methods to detect DNA. One such method is DNA sequence 
identification. Nam, Stoeva and Mirkin (2004) identify another method of DNA detection: the 
method of polymerase chain reaction itself. PCR has had a powerful influence in the medical and 
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biological communities. It revolutionized medical diagnostic systems that depend on quantifying 
and detecting DNA. However, PCR is criticized for its costly, complex, labor-intensive and time-
consuming process, and wider target range of DNA quantification after amplification.  
According to Gaylord, Heeger and Bazan (2002), DNA sequence identification methods are of 
huge economic and scientific interest. Their application involves examination of genetic 
mutations, medical diagnostics, specific genomic techniques and gene delivery supervision. 
Wang (2000) has mentioned that cationic organic dyes such as thiazole orange and ethidium 
bromide discharge when intercalated inserted into the double stranded DNA grooves, and serve 
as direct hybridization probes of DNA. Schork et al. (2000) described the difficulties in 
simultaneously labeling two sites of DNA, resulting in reduced yields, greater costs and 
individually labeled impurities which reduce detection sensitivity. Most of the motivation behind 
developing DNA detection methods is to enhance economic and procedural factors for 
estimating strand-specific hybridization that uses homogenous fluorescence assays easily, with 
reduced DNA alterations, and developing amplification of signals.  
Bustin (2002) has mentioned that numerous assays of DNA detection have been 
expanded using molecular fluorophores, radioactive labels, electrochemical tags, 
chemiluminescence schemes, and labels based on nanostructure. Makrigiorgos et al. (2002) 
stated that it would be beneficial for a researcher to expand a methodology that permits for PCR-
like amplification of signal and eliminates its disadvantages. A biological bar code-based 
approach can detect the targets of DNA in addition to targets of protein. According to 
Nicewarner-Pena et al. (2001), a novel approach to detect DNA has been developed that offers 
greater selectivity with a sensitivity that is comparable to numerous PCR based approaches 
without the requirement for enzymatic amplification. The major benefit of the DNA bio bar code 
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approach over conventional microarray sandwich assays is that the complete assay can be 
performed in three to four hours regardless of target concentration. The system has a dynamic 
range and is ideal for multiplexing.   
Gillet, Mori, van Esbroeck, van den Ende, and Jacobs (2009) have identified the biosensor 
as the analytical instrument used in analyte detection–the mixture of the biological component 
with a physicochemical detector. DNA biosensors involve the use of DNA as sensory devices 
that could theoretically be used in medical diagnostics, agriculture, and forensic science and in 
environmental clean-up, food analysis, the study of bimolecular reactions and their interactions, 
drug development, crime detection, medical diagnostics, environmental field monitoring, quality 
control, industrial process control, detection systems for biological warfare agents, and the 
manufacturing of pharmaceuticals and replacement organs. Mathur et al. (2012) has mentioned 
that there are four types of DNA-based biosensors: optical, piezoelectric, DNA chips and 
electrochemical biosensors. Piunno et al. (1994) noted that optical biosensors of DNA are based 
on fiber optics, which transduces an emission signal to a fluorescent label and can conduct light 
from one place to another via internal inflections. The advantages of optical biosensors are the 
sensitivity of optical approaches and the use of portable instruments; however, they suffer the 
disadvantage of the high cost associated with the equipment. According to Kerman, Kobayashi 
and Tamiya (2004), electrochemical biosensors of DNA are useful for sequence-specific DNA 
biosensing. The inherent miniaturization of electrochemical components and advanced micro-
fabrication techniques make biosensors a powerful tool for DNA identification. Lazerges et al. 
(2006) discussed the piezoelectric biosensor of DNA as a mass-sensitive tool which relies on 
quartz crystals that oscillate at defined frequencies when oscillation voltage is applied. Attention 
has been given to development of the piezoelectric method due to its low cost, real-time label-
  
5 
 
free detection, sensitivity and simplicity. Arora and Malhotra (2008) described DNA biochips as 
solid, small devices which themselves are microscopic slides, but can be nylon membranes or 
silicon chips onto which sequences from thousands of different genes are attached or 
immobilized at fixed places.  
1.2. Lateral Flow Nucleic Acid Biosensor 
According to Henderson (2000), Lateral Flow Biosensors is a technique that is used to 
detect proteins, small molecules and viral antigens. This enables the rapid POC (point of care) 
diagnosis of infections and diseases like malaria, dengue fever and HIV. The lateral flow 
biosensor technique also detects cardiac markers, cancer etc. The lateral flow format uses a 
sandwich-like structure such as that used in immunoassay: it has two antibodies that are bound to 
perform sandwich-style analysis. One antibody, mAb, is bound, initially non-covalently, in a 
horizontal stripe on a narrow strip of nitrocellulose. The nitrocellulose is void of protein to avoid 
vague observance of analyte and other proteins. The analyte and a second labeled antibody 
(classically, it is labeled with colloidal gold) are permitted to stream up nitrocellulose. 
Edwards (2006) has mentioned that the existing lateral flow (immuno-) assay (LFA) 
methods are the association of a fluid model, or its extort surrounded the analyte besides a slip of 
polymeric material thus fleeting separated zones wherever molecules have been naïve of further 
or fewer brief communication with  analyte. Several layouts have been described for LFAs. 
These layouts are chosen on the basis of the desired analyte. Mudanyali, Dimitrov, Sikora, 
Padmanabhan, Navruz, and Ozcan (2012) have described several possible layouts for the lateral 
flow of nucleic acid, especially in third-world countries. These tests are acceptable for 
biomedical applications since there is no need to keep the strips refrigerated. They have a long 
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shelf life with little variation in the quality of batches. LFAs are intended for single-use 
applications, so there is no risk of prior-use contamination.  
Carter and Cary (2007) have identified a method to detect DNA using LFAs. Lateral flow 
detection of RNA or DNA amplification reaction products offers a method of simplifying 
detection of nucleic acids. Dineva et al. (2005) has mentioned that lateral flow devices have been 
fabricated predominantly using more than one capture line, permitting more than one analyte. As 
a step toward improving information detection of lateral flow nucleic acids, the researchers have 
developed nitrocellulose patterning methods that allow microarray characteristic densities to be 
met on compatible substrates of lateral flow. Thus, the lateral flow microarray method develops 
sequence-specific detection, opening the door to increasingly multiplexed implementations for a 
vast number of assays, well-suited for point of care and other field applications. 
1.3. Sexually Transmitted Infections 
Sexually transmitted infections (STIs) also referred to as sexually transmitted diseases or 
venereal diseases. These infections are primarily passed from one person to another sexually. 
STIs can spread through vaginal, anal or oral sex, or through some other non-sexual means, such 
as the sharing or re-use of sub-dermal needles. About 25 different types of STIs are known that 
show a broad range of symptom severity, and in some cases are asymptomatic. Certain STIs can 
also be transmitted from a pregnant woman to her child in utero. The symptoms of STIs vary, but 
common symptoms include: site-specific pain, unusual lumps or sores, pain during urination, 
itching and/or unusual discharge. Most STIs can be cured easily, but if these infections are left 
untreated, they can result in severe symptoms and long term damage (e.g. infertility). Some 
common and most wide-spread STIs are: Chlamydia, gonorrhea and genital warts, which are 
discussed in the following sections in more detail. 
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1.3.1. Chlamydia trachomatis 
Chlamydia is a common sexually-transmitted disease caused by the infection of 
Chlamydia trachomatis (CT).  According to Geisler (2011), CT is a gram-negative bound 
intracellular micro-organism that usually infects squamocolumnar epithelial cells. CT generally 
involves the bacterial strains of the genus Chlamydophila and Chlamydia. CT can be 
differentiated into 18 serologically variant strains on the basis of monoclonal antibody-based 
typing assays. Chlamydia trachomatis is the cause of infections with numerous severe problems. 
Because most of the patients affected by CT are asymptomatic, such that an essential proportion 
of them remain unidentified, the disease can cause infectious outbreak problems. Chlamydia 
trachomatis is conveyed through the mucous membranes of the rectum, urethra, throat and 
conjunctive tissues. Similarly, Hammerschlag (2011) has noted that CT infections infect the 
urethra, cervix, uterus, epididymis, salpinges and nasopharynx. It is usually reported that 
bacterial sexually-transmitted disease in the U.S. is a major cause of sterility in women.  
Chlamydial trachomatis infection influences other diseases as well, including: 
pneumonia, pneumonitis, conjunctivitis and afebrile pneumonia syndrome. According to Manavi 
(2006), CT has been reported to cause similar STI issues in the United Kingdom. In fact, 
untreated chlamydial infection cases can lead to PID (pelvic inflammatory disease), infertility, 
chronic pain and ectopic pregnancy in women. During labor, untreated chlamydia infection can 
be transmitted to the newborn and cause pnuemonitis and conjunctivitis in infants. Therefore, an 
infected mother can infect her baby during vaginal delivery. Untreated chlamydia infections in 
men can lead to epididymo-orchitis. Because of the long-term influence of chlamydial infection 
to young adults’ health, it is essential to identify and treat affected patients and their partners.  
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La Montagne et al. (2004) noted that, although screening programs handled by 
genitourinary medicine physicians are important, it is essential that urologists, general 
practitioners and gynecologists have adequate training and knowledge to handle chlamydia 
infections and its associated health and reproductive problems. Watson et al. (2002) has 
mentioned that the asymptomatic nature of chlamydia infection makes screening important to 
manage the public health concerns of this infection. Jang et al. (1992) stated that, because of the 
seriousness of the problems of CT infection and their impacts on health and economics terms, 
other countries—including France, the United Kingdom, Finland and the Netherlands—have 
taken action to lower the prevalence of CT infection. To be efficient, a national screening 
program must make a precise diagnostic test accessible. It is essential that any test utilized in a 
national screening program can be used in a primary care setting without the requirement for 
costly training. 
1.3.2. Neisseria gonorrhoeae 
Knapp et al. (1994) identifies Neisseria gonorrhoeae (NG) as a bacterium that is 
transmitted sexually and is characterized by a symptom spectrum ranging from asymptomatic 
infection to pelvic inflammatory disease. Gonorrhea is another gram–negative, infectious 
bacterium and a fastidious diplococcic that can develop and multiply rapidly in mucous 
membranes, particularly those of the anus, mouth and throat, and the fallopian tubes, uterus and 
cervix of the female reproductive tract. Uncomplicated gonorrhea infects nearly 650,000 people 
every year. Fox et al. (1997) has described that the commonness of Neisseria gonorrhoeae in the 
United States and abroad, particularly in developing and under-developed countries, has been 
reduced in past two decades. Presently however, greater rates of infection have been discovered 
due to development of antimicrobial-resistant gonococci. The infection of NG can be prevented 
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using safe sexual practices and condoms. According to Hook and Handsfield (1999), the NG 
infection is sometimes asymptomatic among females; if untreated, Neisseria gonorrhoeae 
infection can lead to pelvic inflammatory disease, ectopic pregnancy, chronic pelvic pain and 
tubal infertility. NG generally causes symptomatic urethritis among males, and occasionally 
presents in epididymitis. Rarely, local infection spreads to affect an acute dermatitis 
tenosynovitis syndrome, which can lead to meningitis, endocarditis or arthritis. Neisseria 
gonorrhoeae can cause serious conjunctivitis which can result in blindness if left untreated, and 
can rarely cause sepsis with related meningitis, arthritis or endocarditis. According to the study 
of Unemo and Dillon (2011), NG can affect a newborn's eyes during delivery through the 
infected mother’s birth canal, which can result in blindness.  
Globally, Neisseria gonorrhoeae public health concerns are similar to those for human 
immunodeficiency virus (HIV) and other bacterial STIs. Recognition of cases and efficient 
treatment with antibiotics are primary approaches for control and prevention of NG. However 
Buve, Gourbin and Laga (2008) have mentioned that there are new global concerns considering 
new gonorrhea incidents in several countries, coupled with the prevalence of greater resistance to 
antimicrobial agents previously used for treatment, coupled with with lowered resistance and/or 
susceptibility to modern antimicrobial agents such as extended spectrum cephalosporins and 
azithromycin. Therefore, Tapsall et al. (2009) notes that NG may become untreatable in some 
circumstances, wherein the organism has developed as a “superbug.” International efforts to 
gather data on developing trends in antimicrobial susceptibility, coupled with national, regional 
and international surveillance of epidemiological features and the spread of Neisseria 
gonorrhoeae have become a priority of public health efforts. However the availability of 
performing reliable, phenotypal, antimicrobial testing of susceptibility has been reduced because 
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NAATs (nucleic acid amplification tests) are rapidly replacing the culture for gonorrhea 
diagnosis.  
1.3.3. Human papilloma virus 
Human papilloma virus (HPV) is among the most common sexually transmitted 
infections. HPV is so common that almost all sexually active men and women get it at some 
point in their lives. According to the CDC (2012), human papilloma viruses are small, double- 
stranded viruses of DNA that affect the epithelium. More than 100 types of human papilloma 
viruses have been identified, distinguished by their outer capsid protein L1 genetic sequences. 
Among the strains of HPV known, certain varieties cause health problems such as warts and 
cancers. Those HPV that affect the cutaneous epithelium create warts in the skin. However, 
nearly forty strains affect mucosal epithelia. in addition to causing cervical cancer, infection of 
mucosa by HPV is associated with anogenital cancers, such as cancer of the vagina, vulva, penis, 
and anus.  
According to Munoz et al. (2006), HPV is often not the sole contributing factor to the 
development of cervical cancer. The long-term use of hormonal contraceptives, tobacco use, and 
co-infection ofHIV have been recognized as cofactors to the development of cervical cancer with 
HPV; co-infection with HSV-2 (herpes simplex virus type 2) and CT, some dietary deficiencies 
and immuno-suppression are other likely cofactors.  Bhatla and Joseph (2009) state that HPV 
epidemiology in cervical cancer formed the basis for determining the two most prevalent kinds 
of HPV globally: HPV 16 and HPV 18, which, they state, must be included in first prophylactic 
vaccines against HPV. Compared to most viral vaccines that are based on attenuated virus, a 
vaccine for HPV was not feasible before because there was no efficient system of culturing the 
virus. Roden et al. (1996) described that the human response to genital infections of HPV is 
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characterized mainly by local cell mediated immunity and is related to lesion regression, which 
would then prevent future infection with a similar genotype of HPV. The HPV L1 vaccines of 
virus-like particles that have been developed commercially protect versus HPV 16 and HPV 18, 
which together account for 70% of cervical cancers globally. Roden, therefore, determined that 
an HPV vaccine could be developed based not upon the viral DNA, but the protein coat that 
surrounds it. 
Bharti et al. (2009) described both conventional and alternative therapeutic methods for 
the treatment of HPV. Even after the identification of the causal relationship between cervical  
cancer and HPV, the absence/presence of the virus does not influence treatment 
strategies, which are primarily anti-cancerous. Conventional therapies involve traditional 
Western cancer therapies, such as. Molano et al. (2003) described alternate therapies of HPV, 
involving immunotherapy, photodynamic therapy and treatment with cytotoxic agents.  Though 
excision is the most preferred process for genital warts, topical cytotoxic preparations like 
trichloro-acetic acid and podophyllin acid are used in Europe and the USA. Most of these 
therapies reveal inconsistent or no antiviral response against HPV. Similarly Nagai et al. (2000) 
noted that in immunotherapy, interferons are the only antiviral drugs approved for benign HPV-
related lesion therapy. Photodynamic therapy is a new treatment for various premalignant 
dysplasias and malignant tumors, as well as for non-cancerous indications. Thus, it can be 
inferred that a considerable number of HPV infected immunosuppressed individuals cannot be 
handled with greater cost RNA interference technique or through immunotherapies. 
1.4. Detection of Sexually Transmitted Infections 
Hook et al. (1997) reported that Neisseria gonorrhoeae and Chlamydia trachomatis are 
two of the most widespread sexually transmitted pathogens in the world, with high infection 
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rates among female sex workers in developing countries, a considerable ratio of whom have 
asymptomatic infections. Traditional lab identification of these infections is performed by culture 
for NG and antigen or cell culture detection of CT. Presently nucleic acid amplification tests 
(NAATs) are widely used, and have revealed a high degree of sensitivity predictive ability for 
NG and CT infections. Numerous studies—Schepetiuk et al. (1997), Steingrimsson et al. (1998) 
and Loeffelholz et al. (1992)—have revealed that NAATs are more exact than previous standard 
tests for Neisseria gonorrhoeae and Chlamydia trachomatis. However, it is known that some 
substances in clinical specimens may be related to inhibition of amplification, and NAATs may 
provide false positive outcomes. Presently accessible commercial NG and CT DNA tests of 
amplification involve LCR (ligase chain reaction), SDA (strand displacement amplification) and 
PCR (polymerase chain reaction). According to Kehl et al. (1998), a major barrier for 
comparative studies of varied commercialized nucleic acid amplification tests for detection of 
Chlamydia trachomatis and Neisseria gonorrhoeae in genital swabs is the incapability of 
different specimen gathering and transportation of specimens. To permit a scientifically valid 
comparison and a proper head to head estimation of various diagnostic assays, entire tests must 
be performed on a similar type of specimen, and involve a considerable number of true-positive 
specimens. 
According to Black (1997), chlamydia culturization is regarded as the “gold standard” 
method, as it has nearly 100% specificity. Culture methods can be used for antibiotic testing of 
susceptibility of transmission. The method relies on specimens’ inoculation on a monolayer of 
cells susceptible to CT. The drawbacks of culturization include its reduced 100% sensitivity and 
that it relies on laboratory proficiency. Similarly, the non-culture processes involve enzyme 
immunoassay (EIA), NAATs, nucleic acid hybridization technologies and direct fluorescent 
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antibody (DFA). EIA uses enzymes to detect Lipopolysaccharide on chlamydial elementary 
bodies. Enzyme immunoassay can generate false positive outcomes, and are less sensitive than 
the method of chlamydial culture. DFA is based on the direct visualization of chlamydial 
elementary bodies through combination of monoclonal antibodies to MOMP molecules on the 
membrane. Chernesky et al. (1986) determined that DFA is highly specific, but is not applicable 
for large numbers of specimens because it is labor intensive and time consuming. The techniques 
of nucleic acid hybridization predict rRNA of chlamydia with a complementary probe of DNA.  
The invention of NAAT has revolutionized the identification of chlamydial infection. 
These assays detect and amplify the sequences of nucleic acid distinct to CT in specimens and 
have greater specificity and sensitivity than the techniques described above. These assays do not 
require feasible micro-organisms, and some can predict the existence of an individual nucleic 
sequence in the specimen. Lee et al. (1995) described that the drawbacks of NAATs are their 
price, their lowered performance in the presence of inhibitors in urine samples and the 
requirement to freeze urine specimens to increase test performance.   
According to Ng and Martin (2005), discharge from the urethral meatus is required for 
NG detection. If a post-pubertal patient has no such discharge, an intra-urethral swab can be used 
for gonococci detection. To maximize the detection of organisms, samples must be gathered 
from patients who have not voided for at least two hours. The swabs are used to prepare a smear, 
culturing on proper media or for transport to other laboratories. Tabrizi et al. (2011) noted that 
NAATs can be used for NG detection in samples from extra-genital sites such as the rectum and 
pharynx, which harbor greater number of species of NG and possibly N. meningitidis. The 
performance features of NAAT assays and platforms require precise evaluation. This is achieved 
by using well-characterized isolates of varied species of Neisseria gonorrhoeae and clinical 
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samples. Some of the former studies have estimated that recent generation nucleic acid 
amplification test systems of gonococci—such as Gen-Probe Aptima Combo 2, CT/NG assay on 
m2000, ProbeTec GC Qx assay and Roche COBAS-4800 NG/CT test--have shown high 
concordance compared to other potential targets of nucleic acid amplification tests. Smith et al. 
(1992) mentioned that ligase chain reaction (LCR) was approved by the FDA for Neisseria 
gonorrhoeae detection in urine. LCR was considered the best choice for detecting gonococcal 
culture, because it is highly sensitive for men and women. Its evaluation for discrepant analysis 
is 100 percent accurate for both women and men. Stary et al. (1997) described that the use of 
LCR or PCR for NG detection in rectal specimens has been researched in one study, but had not 
yet been approved by the FDA. In a subsample of men and women for whom a urogenital 
specimen was positive by culture or by ligase chain reaction, LCR detected NG in rectal samples 
in 10 of 22 women and 6 of 47 men, while culture did not detect any infections. Nolt et al. 
(1994) described that the new nucleic acid detection tests, particularly ligase chain reaction, 
provide some benefits over culture, such as flexibility in source of sampling, handling of samples 
and speed of results, all of which encourages their use. LCR may predict numerous infections 
where the conditions for a culture’s optimal performance are absent. In more formal laboratory 
settings where such circumstances are well maintained, the ratio of benefits of LCR to culture 
may be lower.    
According to the study of Jampasa et al. (2014), different techniques have been enhanced 
and used for the identification of HPV infections. Presently, the most widely-used technologies 
for diagnosis and screening of HPV infection are Pap smear test, PCR with genetic primers and 
digene Hybrid Capture assay. However, Villa and Denny (2006) described that these 
technologies have some drawbacks: a reduced specificity for HPV and a sensitivity which 
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requires time consuming expertise and costly and complicated instrumentation. Therefore these 
methods are not suitable for nations with limited personnel and resources. Fu et al. (2004) 
identified new methods of detection such as fluorescence and piezoelectric spectroscopy and 
acoustic wave have been used for HPV detection, but these suffer the need for costly instruments 
as well. However, electrochemical detection of sequences related to HPV has been developed. It 
requires little storage space, has greater sensitivity, portability, and reduced cost and simplicity, 
which makes electrochemical detection a strong contender for a POC (point of care) DNA 
diagnostic process. According to Vilaivan et al. (2011), a new conformationally-restricted PNA 
system of pyrrolidinyl with alpha-beta peptide backbone derived from two acpcPNA 
(aminocyclopentanecarboxylic acid) was developed. AcpcPNA displays a powerful affinity for 
binding and a greater specificity towards a complementary target DNA than PNA or DNA. 
Ananthanawat et al. (2009) noted that, because of these properties, acpcPNA has been used as a 
sensor probe to identify target DNA in combination with different techniques of detection, such 
as matrix-supported ionization/desorption time of flight mass spectrometry, surface plasmon 
resonance and fluorescence microscopy. 
For the testing of HPV in real samples, various methods have been developed since the 
turn of the century. Buger et al. (2011) described that both RNA and DNA tests can be used for 
HPV detection, where the RNA tests detect gene expression (which is similar to detection of 
cancer), and DNA tests detect the absence or presence of an HPV virus genome. Most 
essentially, HPV E7 and E6 are products of a viral gene recognized as being overexpressed and 
deregulated following integration of the virus in a host genome. According to Zur & Hausen 
(2002), over-expression allows for malignancy in cancers related to HPV. The two viral 
oncogenes promote growth of irregular cells by deactivating tumor suppressor proteins pRB and 
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p53. It is mentioned that the detection of E6 and E7 may permit a better differentiation between 
HPVs that are temporary and those that will advance to cancer during primary screening. Malloy 
et al. (2000) has mentioned that, in cervical specimens, direct HPV detection may provide a 
complement or alternative to population-based cytological screening. Schiffman et al. (2000) and 
Wright et al. (2000) described that test results of HPV are more sensitive than Pap smears in 
predicting severe dysplasia in older women. In some cases, women with positive tests for HPV 
still have Pap tests or other diagnostic processes that turn up negative for the virus. Pavonen et 
al. (2010) noted that HPV-18 and HPV-16 AS04 adjuvant vaccine offered security against 
lesions of CIN2+ that were related with HPV-18 and HPV-16, as well as lesions that are 
associated with non-vaccine treatments. Although the significance of regular Pap or HPV tests in 
unvaccinated and vaccinated women must be emphasized, the vaccination of HPV has the 
potential to lower the event of pre-cancer and cervical cancer substantially, as well as the rate of 
cervical excision procedures and colposcopy referrals. 
1.5. Problem Identified 
The detection of nucleic acids is critical for the diagnosis of bio-warfare agents, genetic 
diseases, and other infectious agents. In general, traditional technologies, methods and strategies 
for detecting nucleic acids are labor intensive and time consuming (Zeng, Lie, and Fang, 2013). 
The advent of modern technologies and methods, including the RT-PCR (real time polymerase 
chain reaction), isothermal strand displacement reaction based on chemical or fluorescence 
methods, SPR (surface plasmon resonance) and DNA microarrays provide sensitive and fast 
tools for the detection of nucleic acids. However, these methods still require highly trained 
people and complicated instrumentation. So, the burden is on researchers to identify strategies 
and methods which are fast, low cost, sensitive and easy to use for the detection of nucleic acids, 
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and offer a POC diagnosis for sexually transmitted infections like Chlamydia trachomatis, 
Neisseria gonorrhoeae and HPV-16. This study intends to describe the method of detection of 
multiple nucleic acids based on the Lateral Flow Biosensor and its applications. 
1.6. Aims and Objectives of the Study 
The primary aim of this study is to detect multiple nucleic acid samples simultaneously 
on a Lateral Flow Biosensor. The secondary objective is to apply the bio-sensing platform to the 
detection of PCR-amplified products and to explore its application for real sample detection of 
sexually transmitted infections like Chlamydia trachomatis, Neisseria gonorrhoeae and HPV-16. 
1.7. Significance of the Study 
In biomedicine, detection systems for nucleic acids are critical for several applications in 
order to handle the process of monitoring and diagnosis of illnesses such as genetic material 
based disease detection and infectious diseases (Drummond, Hill, and Barton, 2003). Successful 
treatment of bacterial infection requires particular identification of the causative agent. 
Traditionally, identifying the bacterial pathogens by is the crucial element of the diagnostic 
process (Mothershed and Whitney, 2006). Improvement in traditional methods and approaches 
like automation of blood culture systems requires laboratories to adopt NAATs (nucleic acid 
amplification tests) in order to identify pathogens reliably and rapidly (Kaltsas, Want and Cohen, 
2005).  
The benefit of nucleic acid-based testing includes high throughput, stability, and reduced 
time to diagnosis and accurate results. Apart from these, NAATs provide additional benefits in 
specific organism detection, scenarios of low detection limits (e.g. a single cell) and rapid results. 
The recent advances in NAAT methods and approaches to detect bacteria provide increased 
specificity and sensitivity over traditional microbiological techniques.  
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The Lateral Flow Biosensor developed in this work allows the selective and sensitive 
detection of multiple DNA targets in a complex mixture of nucleic acids. The biosensor has the 
capacity to provide fast and sensitive results. Its nucleic acid based testing method has great 
potential to increase accuracy and speed of nucleic acid based STI detection. The lateral flow 
device provides great selectivity towards other infectious agents as well, allowing it to be a 
potential platform for point of care diagnosis and clinical use.  
1.8. Limitations of the Study 
This study is exclusively focused on detection of nucleic acid samples only. The work is 
also limited to real sample C. trachomatis, N. gonorrhoeae and HPV 16 detection, and no other 
agents are taken into consideration. 
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CHAPTER 2. EXPERIMENTAL TECHNIQUES 
A variety of experimental techniques are described in this chapter. The topics covered 
under this section include the preparation of gold nanoparticles, a method to conjugate thiolated 
DNA oligonucleotides to gold nanoparticle colloid solution, and preparation of a Lateral Flow 
Biosensor including the modification and assembly of each component. A description of each 
technique that was used in this research project is presented hereafter. 
2.1. Gold Nanoparticle Preparation 
Gold nanoparticles are generally prepared in a wet reaction by the reduction of HAuCl4 
(chloroauric acid). After dissolving chloroauric acid, the solution is stirred with continuous 
heating. A reducing agent (citric acid) is added that causes Au3+ ions to be reduced to neutral 
gold atoms. Continuing to heat with stirring reduces more gold ions to gold atoms until the 
solution becomes saturated and precipitates in the form of sub-nanometer particles. To produce 
particles of a larger size, the amount of reducing agent is lowered so that the rate of gold ion 
reduction is decreased. 
Gold nanoparticles (AuNP) with an average diameter of 15 nm ± 3.5 nm were prepared 
according to the method reported by Liu et al. (2009). In detail, a round-bottomed flask was 
cleaned thoroughly with aqua regia (3HCl:HNO3) followed by rinsing with double-distilled 
water. For the synthesis procedure, 100 ml of 0.01% HAuCl4 prepared with ultrapure water was 
boiled with vigorous stirring followed by the addition of 4.5 ml of 1% trisodium citrate. Boiling 
was continued for an additional ten minutes after the solution turned wine red. The heating 
source was removed and the red colloid solution was stirred while cooling for another 15 
minutes. The resulting AuNP solution was stored in dark bottles at 4 °C for future use. The 
AuNP solution was characterized by an absorption maximum at 520 nm to validate the 
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uniformity of the particles and the expected red color of the particles was captured via a camera 
as shown in Figure 1. A concentrated solution of 15 nm gold nanoparticles was further used to 
conjugate with DNA oligonucleotides. 
 
2.2. Gold Nanoparticle DNA Conjugates 
This section outlines the preparation of conjugates between short synthetic 
oligonucleotides (20 to 40 bases in length) and gold nanoparticles (15 ± 3 nm in diameter). These 
conjugates are formed between aqueous gold colloid solutions and synthesized short nucleic acid 
sequences modified with a free thiol or a disulfide group at either end. The AuNPs functionalized 
with multiple oligonucleotides are stabilized against flocculation and precipitation at high ionic 
strength or temperatures. The HPLC purified thiol functionalized oligonucleotide can be 
purchased from Integrated DNA Technologies, California. The gold colloid solution was 
concentrated fivefold before conjugation. Briefly, 5 ml AuNP solution was distributed in five 
Figure 1: Image of 15 nm sized colloidal gold nanoparticle prepared using citrate reduction 
method. 
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tubes equally. The solution was centrifuged at 12000 rpm for 15 minutes at room temperature. 
The pellet from all tubes was collected and re-suspended in 1 ml double distilled water before 
using for conjugation. AuNP conjugation reactions were carried out by adding approximately (33 
µg/ml) 1 O.D. DNA probe to 1 ml of the 5-fold concentrated AuNP solution. After standing at 4 
°C for 24 hours, the solution was subjected to “aging” by the slow addition of NaCl to a 
concentration of 150 mM, and 15 µl of 1% sodium dodecyl sulfate (SDS) to stabilize the AuNPs. 
The solution was allowed to stand for another 24 hours at 4 °C, and the excess of reagents were 
removed by centrifugation for 12 minutes at 12000 rpm. The conjugated solution was washed 
with PBS buffer three times. The supernatant was discarded, and the red pellet was re-suspended 
in 1000 µl of eluent buffer containing 20 mM Na₃PO₄, 5% BSA, 0.25% Tween-20, and 10% 
sucrose. The resulting red colored conjugate solution can be stored at 4°C until further use. 
2.3. Preparation of Streptavidin-Biotin DNA Conjugates 
This section includes the conjugation of DNA oligonucleotides to streptavidin via biotin. 
Streptavidin is a protein composed of four identical subunits each with a high affinity binding 
site for biotin. The bond formation between the two is very rapid and is unaffected by a wide 
range of pH or temperature changes. To facilitate successful conjugation of synthetic 
oligonucleotide to streptavidin, biotin-labeled DNA sequences (20 to 40 bases) were purchased 
from Integrated DNA technologies, CA. The oligonucleotide solution (~50 nmol) was added to 
300 μl of 1.67 mg/ml streptavidin solution and diluted with PBS to make the final volume 500 
µl.  The mixture was incubated for 1 hour at room temperature (RT). The excess DNA probes 
from conjugates were removed in three washing steps with a centrifugal membrane filter (cutoff 
30000, Millipore) at 6000 rpm for 20 minutes each. Finally, PBS was added to make the final 
volume 500 µl and stored at 4°C until further use.  
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2.4. Preparation of Lateral Flow Biosensor 
The Lateral Flow Biosensor consists of four components: a sample pad, a conjugate pad, 
a nitrocellulose membrane and an absorbent pad (Figure 2).   
 
All components are mounted on a common backing layer (typically an inert plastic) using 
the Clamshell Laminator (Biodot, CA). The sample application pad (17 mm × 30 cm) made from 
cellulose fiber (CFSP001700, Millipore, Billerica, MA) was saturated with buffer (pH 8.0) 
containing 0.25% Triton X-100, 0.05 M Tris-HCl, and 0.15 M NaCl for 1 hour at room 
temperature. The treated sample pad was dried at 37 °C for its assembly on the backing layer 
with other biosensor components. The conjugate pad (8 mm × 30 cm), a glass fiber 
(CFSP001700, Millipore, MA) was prepared by dispensing a desired volume of AuNP-DNA 
conjugates solution onto the glass fiber pad with the dispenser Airjet AJQ 3000, dried at RT. 
Nitrocellulose membrane (25 mm × 30 cm) was dispensed with DNA probes at different 
locations to form test and control zones. Biojet BJQ 3000 was used to dispense each conjugate 
on the nitrocellulose membrane with a distance of about 2 mm between each zone. Figure 3 
Figure 2: Schematic representation outlining the assembly of a typical Lateral Flow Biosensor. 
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shows the image of the Airjet AJQ 3000/Biojet BJQ 3000 used for dispensing conjugates on 
different membranes.  
 
The individual, dried membranes are finally assembled on the backing layer to finish the 
biosensor preparation. The sample pad, conjugate pad, nitrocellulose membrane, and absorption 
pad (cellulose fiber sample pads (CFSP001700)) were assembled on plastic adhesive backing (60 
mm × 30 cm) laminated cards (HF000MC100) obtained from Millipore, Billerica, MA. Each part 
overlaps 2 mm to ensure the solution migrates through the strip during the assay. The biosensor 
(3mm width) was assembled and cut using the Clamshell Laminator and the Guillotine cutting 
module CM 4000 shown in Figure 4. The Guillotine cutting module CM 4000 was used to cut 
the biosensor of 3 mm width and stored at 4 °C until further testing. The Lateral Flow Biosensor 
can be stored for 6-8 months at 4 °C without any significant loss in sensitivity, giving it a good 
shelf life. 
Figure 3: Image of Airjet / Biojet dispenser. The inset shows the zoomed section of the outlet 
used for dispensing different solutions connected to stock containers via air pump. 
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Figure 4: Image of a fully automatic workstation, Guillotine cutting module CM 4000 that uses 
data input to cut biosensor to a desired width and speed, providing high-quality precision cuts. 
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CHAPTER 3. DETECTION OF MULTIPLE NUCLEIC ACIDS 
This section outlines a historical introduction to different techniques and methods 
developed for the detection of nucleic acid targets in a sample mixture. Then this chapter focuses 
on the detection of multiple DNA targets on a Lateral Flow Biosensor. The high sensitivity 
achieved via this simple and rapid test provides high selectivity and point of care analysis of 
DNA targets from a sample mixture.  
3.1. Introduction 
Since the 1990’s, the detection and analysis of DNA has become more important in fields 
such as genetics, pathology, and food safety. The realization of DNA diagnostics in general 
demands innovative analytical tools capable of providing high speed, low cost and simple 
methods (Fritzsche and Tanton, 2003). One such technology, DNA microarrays, can conduct 
multiple DNA sequence tests simultaneously on a single sample. Nevertheless, this remarkable 
technology of microarray has its limitations. The readout and fabrication of the test must be 
miniaturized in order to obtain easy readout without false responses from non-target sequences. 
In addition to high sensitivity provided by microarray techniques, combination with florescence 
detection allows for multicolor labeling of single-stranded DNA targets, providing highly 
sensitive readouts. But these tests also have the disadvantages of expensive labeling and 
instrumentation. Such demands have encouraged the development of new diagnostics: DNA 
sensors and high density DNA arrays. These analytical techniques provide a great tool for rapid 
and low cost detection, but lack high sensitivity and selectivity (Ramsay 1998). Although high 
sensitivity can be achieved with amplification (e.g. PCR amplification of samples), providing 
small-sample detection down to single cell or a few copies of genomic DNA, effective 
discrimination against mismatch/non-complementary nucleic acids and other biomolecules are 
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also required for effective analysis and reliable point of care testing (Wang, 2000 and 
Christopoulos, 1999).  
3.2. Brief Literature Survey 
In last decade, advances in technology have driven a number of research groups to 
develop DNA detection methods using lateral flow assays: prefabricated strips containing dry 
reagents that are activated upon application of the fluid sample. Such assays are important for 
diagnostic purposes of not just small DNA targets, but to determine pregnancy, infection, 
contamination and abuse of illicit drugs (Schuurs et al., 1980; Gelder et al., 1993). These assays 
usually provide results in 20-30 minutes where a binary output (positive/negative) is sufficient. 
Recently, the sensitivity and selectivity of such assays has been improved by combining thin-
layer chromatography, antigen-antibody or DNA/RNA specific reactions, and/or labeling of the 
target analyte with a recognition element (e.g. fluorophoric tag) (Ullman et al., 1980; Hockmeyer 
et al., 1983; Lee et al., 2006). Lateral flow test strips have been well established in an attempt to 
develop highly accurate results cheaply. A typical lateral flow assay format contains a surface 
layer to carry sample solution along the strip via the conjugate pad. This helps the mixture 
encounter the test/control zones of the membrane moving further up to the absorbent pad. The 
detection label is usually made of a colored or fluorescent material nanometers in size. 
Commonly used labels that allow unobstructed flow through the membrane are often colloidal 
gold (Kapil et al., 2002; Torii et al., 2007; Yang et al 2006; Haasnoot et al., 1998), latex (Smith 
et al., 1997), selenium (Gordon et al., 1993), quantum dots (Mattoussi et al., 2004), carbon 
(Carlson and Lonnberg, 2001) or liposomes (Baeumner et al., 2004, Price et al., 2004, Wauchope 
and Ho 2002; Chen et al., 2008; Huang and Ho 2005). The first application of a lateral flow test 
was the assay for pregnancy determination (Schuurs et al., 1980). The speed and visual output of 
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the result to the naked eye provided a one-step, low cost analysis. The sensitivity of this study’s 
Lateral Flow Biosensors can be further enhanced by the use of nanomaterial labels and novel 
signal amplification strategies (Wang, 2005). 
Since the emergence of nanotechnology is opening new doors for analytical chemistry, 
nanoparticles are garnering considerable worldwide interest because of their unique chemical 
and physical properties Niemeyer, 2001, Mirkin et al., 1998). The power of such nanoparticles is 
greatly enhanced and utilized in recognition and electrochemical assays. The rising interest in 
tailoring and functionalizing the surfaces of nanoparticles has a profound impact on bio 
analytical applications in the field of DNA detection. Due to their great potential, nanoparticle-
based testing relies on optical detection using gold nanoparticles. The hybridization-induced 
cross-linking of gold colloidal particles due to surface oligonucleotides triggers a red to purple 
color change in solution. Such assays have the ability to simultaneously analyze multiple target 
molecules in a sample mixture (Mirkin and Storhoff, 1999; Willner, 2002). High sensitivity can 
be obtained by using fluorophore tags or raman-active dyes (Mirkin et al., 2000, 2001, 2002). 
Nanoparticles offer an elegant way to recognize DNA with high sensitivity and specificity using 
electrochemical-based detection or amplification strategies involving tags and dyes (Nie et al., 
2001, Neimeyer, 2001). High sensitivity provided by nanoparticles can be combined with 
selectivity and the easy application of lateral flow devices to develop an elegant, simple 
detection platform for multiple DNA targets. 
In this chapter, further focus is now provided on the use of gold nanoparticles on a 
disposable Lateral Flow Biosensor for the sensitive and point of care (POC) detection of multiple 
nucleic acid targets. This work combines the unique optical properties of gold nanoparticles and 
highly efficient separation on a chromatographic platform. The sandwich-type DNA 
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hybridization reactions performed on the lateral flow device enable a fast detection method 
without multiple incubation, separation and/or washing steps compared to conventional 
techniques.  
3.3. Lateral Flow Biosensor 
The Lateral Flow Biosensor was designed in the manner described in section 2.4 with 
slight modifications. The sample application pad was saturated with a buffer and dried before 
assembling on the backing layer of the lateral flow device. The AuNP-DNA conjugates were 
also prepared according to the procedure described in the previous chapter. Since the work 
focuses on multiple target detection, two sets of AuNP-DNA conjugates were prepared using 
Thio Probe 1 and Thio Probe 2, described below. A desired volume of AuNP-DNA conjugate 
mixture was dispensed using the Airjet 3000 on the glass fiber membrane used as the conjugate 
pad during biosensor assembly. The nitrocellulose membrane was dispensed with three 
conjugates of streptavidin-biotin DNA conjugates at different sections of the membrane, 
identified as test zone 1, test zone 2 and the control zone. The streptavidin-Biotin DNA 
conjugates were prepared using the Test Probes 1, 2 and 3, described below. The different zones 
of the nitrocellulose membrane were dispensed using Biojet 3000 with desired volumes which 
can be achieved by dispensing multiple cycles. The Lateral Flow Biosensor was assembled by 
combining the individually-developed strip components.  
The following sequences designed for the Lateral Flow Biosensor were purchased from 
Integrated DNA Technologies, CA. 
Target 1 
5’-ATGAAGAAGGCCTTCGGGTTTGTGTGGGAAGGGAGTAAAGTTAATACC-3’ 
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Test Probe 1 (Test line for Target 1) 
5’-Biotin/GTCAATGAGCAAAGGTATTAACTTTACTCCCTTCC-3’ 
Thio Probe 1 (Target 1) 
5’-ThioMC6-D/CTGAAAGTACTTTACAACCCGAAGGCCTTCTTCAT-3’ 
Target 2 
5’-AGACCATCCTGGCTAGTCTGTTGTCTCTACTAAAAATA-3’ 
Test Probe 2 (Test line for Target 2) 
5’-Biotin/CGCCCGGCTAATTTTTTGTATTTTTAGTAGAGAC-3’ 
Thio Probe 2 (Target 2) 
5’-ThioMC6-D/GGGGTTTCACCGTGTTAGCCAGGATGGTCT-3’ 
Probe 3 (Control line) 
5’-ATGAAGAAGGCCTTCGGGTTGTAAAGTACTTTCAG-3’ 
Figure 5: Analyzer DT 1030 to read color intensity of the red band on the Lateral Flow 
Biosensor. 
 
3.3.1. Test procedure 
Sample solution for testing was prepared by diluting a desired concentration of target 
DNA in ¼ SSC, 4%BSA. 100 µl solution was slowly applied to the sample pad of the Lateral 
Flow Biosensor slowly using a micropipette. The test/control zones on the nitrocellulose 
membrane were observed for the appearance of one or more red bands at the test/control zones 
  
30 
 
for 20 minutes. For quantitative results, the strip was inserted into the strip reader DT1030 
(Figure 5), the optical intensities of the test lines and the control line were recorded 
simultaneously by using the “GoldBio strip reader” software. 
3.3.2. Working principle of the Lateral Flow Biosensor 
The principle of detection is based on an on-strip sandwich DNA hybridization reaction 
(Figure 6). The detection solution containing desired concentrations of the target DNA is applied 
to the sample application pad. Via capillary action, the solution moves toward the conjugate pad 
on the strip resulting in hybridization of target DNA to their complementary DNA probes 
conjugated on AuNPs. The conjugate probe sequence is designed to hybridize with half of the 
sequence for each target DNA introduced. The solution containing target DNA-conjugate DNA 
hybrid migrates further on the lateral flow strip and interacts with the probes immobilized on the 
test/control zone of the nitrocellulose membrane.  
The DNA probes are immobilized on the test or the control zone via interaction between 
nitrocellulose membrane and the streptavidin conjugated to biotin DNA (Test Probes 1 or 2, 
respectively). Each test zone contains DNA oligonucleotides complementary to the second half 
of their respective DNA targets. The migration of the target-conjugate hybrid towards the test 
zones results in the formation of the sandwich complex with their complementary probes on the 
membrane. The sequence-specific binding of the three oligonucleotides on the test zone results in 
the appearance of a red band due to the accumulation of AuNP labeled with DNA 
oligonucleotides. The intensity (color) of the red band increases with the amount of target DNA 
present in the sample solution. If one or both target nucleic acids are not present in the test 
solution, only one line is observed on the lateral flow biosensor, denoted as the control zone.  
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Figure 6: Schematic illustration of the working principle on a Lateral Flow Biosensor for the 
simultaneous detection of two nucleic acid targets. 
 
The control zone contains immobilized oligonucleotides that are fully complementary to 
the oligonucleotides labeled on the gold nanoparticles. The free, un-hybridized AuNPs pass over 
the test zone and form double stranded complexes on the control zone of the strip. This results in 
appearance of a red band at the control zone even in the presence or absence of either/both 
targets. This confirms the proper function of the lateral flow biosensor. 
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3.4. Optimizations of Different Parameters 
The formation of red band on the test zones and the control zone were used for the 
qualitative and quantitative analysis of the target DNA. Various conditions were optimized to 
improve the performance of the biosensor.  
Different running buffers were employed for the detection of nucleic acid targets as 
shown in Figure 7. The optimization was performed in the presence of 50 nM concentration of 
Target 1. Best results were obtained in the presence of buffers BSA and SSC.  
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Figure 7: Bar graph comparing the effect on signal intensity on using different running buffers in 
the presence of 50 nM target DNA 1.The SSC buffer, well known for its ability to successfully 
enhance DNA hybridization, was used in combination with BSA. The running buffer capability 
was further improved by individually studying the amount of SSC and BSA in the running 
buffer. Figure 8 shows different concentrations of SSC diluted from the stock solution of 20x 
concentrated buffer. 
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Figure 8: Graph showing different dilutions of 20X SSC buffer employed as running buffer in 
the presence of 1% BSA. 
 
Different tests with same target concentration gave different signal response with varying 
concentration of SSC. 4X was chosen as the optimum as concentrated SSC had obstructed 
movement and resulted in high background in sample reading. The second component of the 
buffer, BSA, was also optimized (Figure 9). Different percentages were added to obtain the best 
signal for 50 nM target concentration. The test was performed in combination with 4X SSC and 
4% BSA was determined to provide the best results. Addition of BSA in the buffer removes 
unwanted adsorption of AuNP conjugates on the nitrocellulose membrane. 4% BSA was chosen 
as an optimum amount used for the running buffer that gave the best signal versus background 
noise. Higher amounts of BSA gave false responses for control conditions, in the absence of 
target DNA due to accumulation/adsorption of AuNP conjugates on the test zones.  
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Figure 9: Bar graph illustrating the different percentage of BSA used in the running buffer with 4 
times diluted SSC buffer for a target concentration of 50 nM. 
 
Further optimizations were performed on the lateral flow strip by changing the amount of 
Thiolated DNA probe labeled on the AuNP. As shown in Figure 10, different concentrations (0.1 
OD, 0.5 OD, 1.0 OD, 2.0 OD and 3.0 OD) of DNA probe were added to the AuNP for the 
preparation of nanoparticle conjugates. Increased concentrations increased the signal intensity on 
the Lateral Flow Biosensor up to 1.0 OD. Higher concentrations of DNA probe for AuNP 
conjugates did not significantly affect the signal response. Hence, 1.0 OD DNA for 1 ml AuNP 
was chosen as the optimal amount of oligonucleotide for the preparation of each conjugate. 
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Figure 10: Graph showing different amount of oligonucleotide labelled on 1 ml AuNP solution 
during conjugate preparation used on the lateral flow device. 
Figure 11: Graph showing varying signal response with the use of different dispensing cycles of 
gold labeled conjugates during the lateral flow biosensor preparation for 50 nM target DNA. 
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After conjugate preparation, the amount of AuNP-DNA conjugates dispensed on the 
conjugate pad of the Lateral Flow Biosensor was optimized (graph shown in Figure 11). 
Different dispensing cycles with Airjet 3000 were used to obtain a conjugate pad with different 
amounts of AuNP-DNA conjugates. Each dispensing cycle resulted in more conjugate on the 
strip which further enhanced the intensity of the band. Two dispensing cycles were chosen as the 
optimum amount of conjugate with maximum signal response and minimum background.  
Other conditions such as the type of nitrocellulose membrane (Figure 12), and the amount 
of test and control probe on the membrane were optimized. Two types of membranes HFB18004 
(3 min) and HFB 24004 (4 min) were used in the preparation of the Lateral Flow Biosensor. 
Better sensitivity was obtained with the 4 min membrane due the slower movement of the 
solution, allowing more complete DNA hybridization.  
The test and control zones were prepared using different dispensing cycles for the 
streptavidin-biotin probes on the membrane (Figure 13). DNA probes with final concentrations 
of 50 nmol were dispensed twice on the nitrocellulose membrane when preparing test/control 
zones to achieve maximum signal response without interference from free AuNP probes. 
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Figure 12: Graph comparing the response from use of two different membrane types used in the 
preparation of lateral flow biosensor. 
Figure 13: Graph showing the response from the use of different number of dispensing cycles of 
capture/control probes on the nitrocellulose membrane of the lateral flow biosensor. 
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3.5. Results and Discussion 
Under these optimized conditions, the Lateral Flow Biosensor was tested for the presence 
or absence of the target DNA as illustrated in Figure 14. The presence of target DNA was 
confirmed visually via the appearance of a red line on the test zone. The quantitative detection 
was performed by measuring the intensity of the red band due to the accumulation of the AuNP 
conjugates on a portable strip reader. Figure 14 shows a typical Lateral Flow Biosensor image 
recorded from a portable strip reader camera. The test was performed in the absence (A) and the 
presence of target 1 (B), target 2 (C), and both targets (D) simultaneously. The response indicates 
that the presence of either or both targets do not interfere with the accurate working of the 
Lateral Flow Biosensor.  
Figure 14: Shows the photographic signal response from (A) absence of nucleic acid in test 
solution, (B) presence of 50 nM Target 1 in 100 µl sample solution, (C) presence of 50 nM 
Target 2 in 100 µl sample solution and (D) presence of both targets in 100 µl solution. 
 
Different concentrations of target DNA (0 nM, 0.1 nM, 0.5 nM, 1.0 nM, 5.0 nM, 10 nM, 
50 nM, 100 nM and 200 nM) were tested thrice each. A red band in the control zone appeared in 
the presence or the absence of any or both DNA targets, validating the function of the Lateral 
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Flow Biosensor. The intensity of the red line on the test zone increased with increasing 
concentration of the target in the sample solution. Figure 15 shows the combined response and 
Figure 16 shows the calibration curve in the presence of different concentrations of each target 
DNA. The increasing concentrations of the target DNA shows increase in signal intensity for a 
linear response till 200 nM, and a minimum detection limit of 0.1 nM for both targets.  
Figure 15: Signal Intensity recorded using Portable Strip Reader in the presence of two targets at 
varying concentration.  
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Figure 16: The calibration curve for target 1 and 2 with a detection limit of 0.1 nM for each 
target nucleic acid. Inset shows the linear curve for lower concentrations (0 nM to 1.0 nM) 
 
The Lateral Flow Biosensor was also tested for interference from other biological 
components like non-complementary oligonucleotides (randomly designed) and proteins (IgG, 
IgM, thrombin, PDGF). These tests were performed with non-complementary DNA or protein in 
the sample solution with and without target DNA. The results indicate that the biosensor showed 
no decrease in sensitivity and proved to be very selective for the desired target(s) only. The 
reproducibility of the biosensor system was analyzed by repeat testing of six strips with different 
target concentrations. The Relative Standard Deviation obtained was 5.5%. 
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3.6. Conclusion 
In this chapter, a platform for simultaneous detection of multiple nucleic acid sequences 
in a sample mixture was developed. The DNA targets could be easily acknowledged by 
observing the appearance of the red band and quantified using the portable strip reader 
instrument. The Lateral Flow Biosensor, as optimized, allows for selective detection with a limit 
of 0.1 nM for each synthesized oligonucleotide. Because of high sensitivity, this approach is 
capable of recognizing and detecting nucleic acids in about 20 minutes visually. The work is 
further improved by altering the methodology in order to lower the detection limit, yet 
maintaining the biosensor’s selectivity to the chosen target analyte.  
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CHAPTER 4. SIGNAL AMPLIFICATION 
This chapter introduces a novel application of a new method for the preparation of gold 
nanoparticle (AuNP) DNA conjugates introduced by Hsing et al. (2009). The method developed 
in this work requires fewer reagents and time to provide a highly sensitive method to detect DNA 
on a Lateral Flow Biosensor. This section further outlines an introduction to various methods 
used to conjugate AuNPs to oligonucleotides over the last decade, and its advantage over other 
amplification strategies used to detect single-stranded nucleic acids. 
4.1. Introduction 
Gold nanoparticles have exhibited various interesting physical and chemical properties 
which make them interesting candidates for visual detection and an integral part of research 
(Burda et al., 2005). In addition to their remarkable optical properties, AuNPs can be stabilized 
using a wide variety of molecules including the most commonly used thiol-modified 
oligonucleotides (Love et al., 2005). DNA-functionalized AuNPs play an important role in the 
fields of bio-sensing and nanotechnology. More recently, the advantages offered by 
functionalized AuNPs have been used for the detection of proteins (Thanh & Rosenzweig, 2002), 
carbohydrates (Otsuka et al., 2001), metal ions (Kim et al., 2001; Liu & Lu, 2003) and nucleic 
acids (Liu et al., 2009). Sensitive DNA detection is extremely important and great efforts have 
been made to develop new strategies to improve selectivity and sensitivity of these assays (He et 
al., 2000; Wang et al., 2002; Makrigiorgos et al., 2002). Such techniques offer optical detection 
via DNA hybridization and base-coupled reactions in conjugation with AuNP labeled with 
oligonucleotides (Weiss, 1999; Fang & Tan, 1999). The absorption frequency from metal 
nanoparticle aggregation depends on the size and distance between two metal particles; hence, 
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detection methods that use color change (red to purple) are also widely used (Elghanian et al., 
1997; Mirkin et al., 1996; Storhoff et al., 2000). 
4.2. Brief Literature Survey 
The striking advantages offered by gold nanoparticles loaded with multiple 
oligonucleotides has enabled their applications in molecular diagnostics (Xu et al., 2007; Lee et 
al., 2007; Nam et al., 2003; Park et al., 2002; Elghanian et al., 1997), nanofabrication (Alivisatos 
et al., 1996; Mirkin et al., 1996; Park et al., 2008; Nykypanchuk et al., 2008), cell imaging 
(Seferos et al., 2007), molecular nano-electronics (Cohen et al., 2005; Cohen et al., 2006; Ullien 
et al., 2007), and gene regulation (Rosi et al., 2006). Since DNA hybridization offers great 
advantage in detection assays, labeling techniques like a florescent dye or an enzyme molecule 
(e.g. HRP) is often used to increase sensitivity of detection systems. Using fluorophores such as 
organic dyes on DNA probes lowers the detection limit, but suffers many disadvantages as well: 
the challenge is the poor photo-stability of many fluorophores and the limit to the number of 
molecules labeled on each DNA conjugated on AuNP. Use of organic dyes also results in serious 
photo–bleaching, and hence, irreproducible signals. Other nanomaterials used are quantum dots, 
silica and metal nanoparticles (Chan et al., 1998; Cao et al., 2002; Maxwell et al.,. 2002; Li et al., 
2002; Taton et al., 2000; Santra et al., 2001). Among them, AuNPs still remains the most widely 
used, with relatively high sensitivity and stability. There are many strategies and methods used 
for preparing AuNPs conjugated with DNA probes, which include direct adsorption of alkylthiol 
or disulfide-labeled oligonucleotides on the surface of AuNPs (Mirkin et al., 1996). Covalent 
binding of oligonucleotides to pre-activated surfaces of metal nanoparticles (Pathak et al., 2001) 
and adsorption of biotinylated probes on the particles, coated with surface avidin (Alivisators et 
al., 1996; Niemeyer et al., 1998) are among other methods used inconjugation. The most widely-
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used method employed for conjugation of oligonucleotide on the metal nanoparticle surface is 
the functionalization of 5’ or 3’ end of the nucleic acid with an akylthiol group (Mirkin et al., 
1996). The easy modification of such groups at nucleic acid termini and the strong affinity 
between AuNP and thiol groups makes them the most stable conjugates among other commonly-
used procedures. With all of these possible procedures, it is necessary to understand the 
importance of the coverage of the DNA on the nanoparticle. Usually, better results are obtained 
with higher loading efficiency to increase the magnitute of detection. Another important factor to 
be considered is the time consumed in the preparation of these conjugates, and the stability of 
each particle to provide fast and reproducible results.  
The most commonly-used method of self-assembly of thiol modified DNA strands on 
AuNP was developed by Mirkin and coworkers in 1998. This approach follows a two-day 
incubation process to directly link thiol-terminated oligonucleotides to citrate-stabilized AuNPs. 
The process also requires further incubation of 40 hours to complete the aging process after the 
addition of NaCl to achieve high loading efficiency and stable conjugation. The procedure was 
eventually improved by Brust et al (2003) who used vacuum centrifugation to speed the process 
and eliminated the aging step which saved about 20 hours. Another conjugation method was 
reported by Alivisatos et al (2005, 2007) to minimize the salt effect by coating AuNPs with bis-
(p-sulfonatophenyl) phenylphosphine dehydrate dipotassium salt before the immobilization of 
thiol labeled oligonucleotides on AuNPs. The process reduced the preparation time to 12 hours. 
The process of conjugation still needed improvement until the work done by Hsing et al. in 2009: 
the group introduced a new conjugation method that enabled rapid immobilization of thiolated 
DNA probes on a stable AuNP in the presence of salt. This novel method relied on fast and 
reversible binding of mononucleotide on the surface of AuNPs. Compared with conventional 
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methods that require overnight incubations and delicate control of ionic strength; this method 
enabled synthesis within 4 hours at high ionic strength. The stable conjugates with about 80 
DNA strands per particle were prepared in 0.1 M salt solution at 60°C without need of special 
equipment.  
This novel approach of conjugation was applied in this work to enhance the labeling 
efficiency of DNA on AuNP, thereby increasing the sensitivity of the system. The approach was 
applied for the detection of single-stranded nucleic acid targets and its application for the 
detection of human genomic DNA. The high sensitivity of this system comes from the direct 
amplification of the signal due to the number of DNA strands that can be loaded onto a single 
AuNP. The amount of DNA on each AuNP directly correlates to amplification, and therefore a 
lower detection limit is achieved. Further details covering the procedures and methods used for 
the assay are discussed in upcoming sections.  
4.3. AuNP-DNA Conjugate Preparation 
Preparation of AuNP-DNA conjugates was according to the method described by Hsing 
et al. (2009) with slight modifications. To a fivefold concentrated solution of gold nanoparticle 
colloid, which was prepared according to the procedure described in Chapter 2, approximately 7 
µM dATP was added. The mixture was incubated at room temperature for 15 minutes before 
addition of salts for aging. Slowly, the mixture was brought to a concentration of 0.015% SDS 
and 0.1 M NaCl before addition of thiolated oligonucleotide (0.25 O.D. / 8.25 µg/ml). The AuNP 
solution containing DNA probes is incubated for 3 hours in a water bath at 60 °C. The solution is 
centrifuged at 12000 RPM at room temperature followed by three washing cycles with PBS 
0.1M solution. The AuNP pellet is re-suspended in 1 ml Eluent Buffer (20 mM Na₃PO₄, 
5%BSA, 0.25% Tween 20 and 10% sucrose) and stored at 4 °C until use. This method was 
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predicted to load more DNA strands on each nanoparticle compared to the older preparation 
method described in Section 2.2, as illustrated in Figure 17. 
Figure 17: Illustrates the comparison between Standard method used by Liu et al (2009) (Old 
Method); common method for preparation of Gold-Nanoparticle-DNA conjugates and the 
Altered Hsing et al. (2009) (New Method); the procedure used in this research. 
 
4.4. Lateral Flow Biosensor 
The Lateral Flow Biosensor for the detection of a single nucleic acid target was prepared 
in the manner described in Chapter 2. The nitrocellulose membrane was prepared with one test 
line and one control line. The streptavidin-biotin DNA conjugates were prepared using two 
oligonucleotide sequences, shown below:  
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Target 1 
5’-ATGAAGAAGGCCTTCGGGTTTGTGTGGGAAGGGAGTAAAGTTAATACC-3’ 
Test Probe 1 (Test line for Target 1) 
5’-Biotin/GTCAATGAGCAAAGGTATTAACTTTACTCCCTTCC-3’ 
Thio Probe 1 (Target 1) 
5’-ThioMC6-D/CTGAAAGTACTTTACAACCCGAAGGCCTTCTTCAT-3’ 
The target sequence chosen here was same as in the work for multiple target DNA 
detection (Chapter 3). The sequence of the target is a part of human genomic DNA, and therefore 
the recognition probes used on the biosensor can also be used for the detection of real samples 
(i.e. human genomic DNA).  
The biosensor prepared for this work also compared the new conjugates (Section 4.3) 
with the traditional method of conjugate preparation (Section 2.2). Hence, two different sets of 
strips were prepared that varied in the type of conjugate used.  
4.4.1. Test procedure 
The sample testing was performed by diluting desired amount of target to a final volume 
of 100 µl using ¼ SSC + 4% BSA buffer. The sample was pipetted slowly onto the sample pad. 
After 10 minutes, 20 µl of the same buffer was added and the biosensor was kept at room 
temperature for another 20 minutes. The intensity of the signal (red line) was recorded using the 
portable strip reader DT1030. 
Human blood serum was spiked with target DNA to mimic real sample conditions. 10 l 
of undiluted human serum was successfully detected on the biosensor without any interference 
from the components of the mixture. Tests were performed by diluting sample in running buffer 
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to a volume of 100 µl and pipetting on the strip. Signal intensities were observed visually and 
recorded via a portable strip reader for quantitative response. 
Human genomic DNA (obtained from Sigma Aldrich, USA) was also tested on the 
biosensor. The desired concentration of the double-stranded human genomic DNA was incubated 
in boiling water for 10 minutes to denature the double helix, then cooled in ice water for another 
10 minutes to avoid re-annealing of the single strands. A total volume of 100 µl (diluted with ¼ 
SSC + 4% BSA) was pipetted on the sample pad. The biosensor was observed for a red band at 
the test zone and the control zone of the strip. Appearance at both zones indicated the successful 
detection of Human genomic DNA. 
4.4.2. Working principle 
Since this work is a further improvement of the detection of single DNA targets on a 
Lateral Flow Biosensor, the principle behind the detection remains the same as described by Liu 
et al. (2009). Briefly, the thiolated probe DNA which was attached on AuNP was designed to be 
complementary to a part of the target DNA. The other half of the target DNA was 
complementary to the DNA probe which was dispensed onto nitrocellulose membrane as the test 
line via streptavidin-biotin linkage. The addition of target DNA on the sample pad moves the 
solution via capillary forces towards the conjugate pad and the target DNA hybridizes with the 
DNA labeled on AuNPs. This complex moves further towards the nitrocellulose membrane and 
forms a sandwich complex with the immobilized streptavidin-biotinylated DNA probe. This 
leads to the accumulation of gold nanoparticles on the test line creating a macroscopic red band. 
The AuNP-DNA conjugates that did not form the complex moved along the nitrocellulose 
membrane and formed a double stranded complex with the control DNA probe dispensed at the 
control zone of the membrane. These red bands were characteristic of the amount of target 
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present in the sample solution. The intensity of the red band at the test zone increased with the 
increase in concentration of the target DNA, whereas the intensity at the control zone solely 
depended on the amount of conjugate used on the biosensor.  In the case of no target DNA in the 
sample solution (the Control Test), there was no red band observed on the test line. The control 
zone always gave a red band after an assay to confirm the function of the biosensor. 
4.5. Optimizations of Different Parameters 
Various factors were taken into consideration for the detection of the target DNA. Liu et 
al. (2009) reported a sensitive and easy technique for the detection of DNA using gold 
nanoparticles. But the procedure for the preparation of AuNP-DNA conjugate was complicated 
and time consuming: it required 2 days and a higher concentration of the thiolated DNA probe (1 
O.D.). This work describes the same detection method with a lower detection limit and an easier 
and faster technique for preparing conjugates. During the preparation of the AuNP-DNA 
conjugates, multiple conditions were changed and optimized. Figure 18 shows the different 
concentrations of dATP used in the preparation of the conjugates vs. the signal intensity for a 
precise concentration of target DNA. Compared with the different amounts used, 7.05 µM dATP 
gave the best results. More dATP saturated the signal intensity without any significant increase 
in response from target.  
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Figure 18: The graph shows the different amount of dATP used in the preparation of AuNP-
DNA Conjugates. 
 
The next optimization was the amount of DNA (OD) used for preparation the conjugates, 
shown in Figure 19. Of the different concentrations tested, 0.25 OD was the optimum amount of 
DNA. Addition of more DNA was presumed to maximize the oligonucleotides’ density on the 
AuNP, giving maximum signal intensity for the test zone detection. 
 
Figure 19: The graph shows the signal intensity recorded by the use of different concentration of 
DNA in conjugate preparation. 
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Figure 20 shows the comparison of the percentage of SDS in 1 ml AuNP. A final 
percentage of 0.015% gave the best results during the conjugate preparation method. It was 
theorized that a higher percentage of SDS is expected to stabilize the AuNP from aggregating, 
but the signal saturated at 0.015%. Lesser amounts of SDS changed the color of the conjugates to 
dark purple, which is a sign for the aggregation of the particles, and hence the decrease in signal 
intensity.  
Figure 20: Graph showing the comparison of signal intensity in the presence of different amount 
of SDS used during conjugate preparation. 
More optimizations were done with the amount of conjugates on the conjugate pad. The 
optimum volume was determined by optimizing the number of dispensing cycles used for the 
conjugates during the preparation of the biosensor. Figure 21 shows the signal response from 
biosensors prepared containing different volumes of conjugates on the conjugate pad. Dispensing 
three cycles of conjugates provided the best results. Less conjugate resulted in less signal 
intensity, as there was less AuNP-DNA available for hybridizing with the target, and hence the 
intensity of the red band changed. The signal intensity was expected to increase with more than 
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three cycles, but it resulted in high background color on the nitrocellulose membrane because of 
the presence of excess AuNP-DNA which remained un-hybridized. 
Figure 21: Shows the response from test on a lateral flow biosensor with different amounts of 
conjugates dispensed. 
Figure 22: Illustrates the comparison between the signal intensity from the use of different 
nitrocellulose membrane on the Lateral Flow Biosensor. 
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After the optimization of the preparation of conjugate and their amounts on the biosensor, 
other components of the strip were also adjusted. Figure 22 indicates the type of nitrocellulose 
membrane used in the preparation of the biosensor. Out of the two available types of 
nitrocellulose, HFB18004(3min) and HFB 24004(4min), the latter was used because the time 
taken by sample solution to travel through the membrane was about 4 minutes, providing extra 
time for the DNA probes to properly hybridize, providing better results.  
Figure 23: Compares the different number of times the test line was dispensed on the biosensor 
vs the response recorded via the portable reader. 
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Figure 24: Comparison of signal intensity vs the running buffer used on the biosensor 
. 
 
In addition, Figure 23 shows the comparison between the number of dispensing cycles for 
the test line on the nitrocellulose membrane. The results indicated that dispensing the 
streptavidin-biotin DNA conjugates three times gave the best results. 
Finally, different types of running buffers were also tested under the optimized 
conditions. The target DNA was diluted in different buffers, shown in Figure 24. Signal response 
was recorded and ¼ SSC + 4% BSA was selected as the best running buffer with least 
background and high sensitivity for target DNA.  
4.6. Results and Discussion 
A new method was used for the preparation of gold nanoparticle-DNA conjugates, 
requiring less time and fewer reagents. Tests were performed to compare the response from the 
use of conjugates prepared with the traditional method vs. the new method using dATP. The old 
method was used by Liu et al. (2009); the new method required only about 0.25OD of DNA 
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probe and 3 hours preparation time, yet yielded far better results. Figure 25 represents the 
difference in the signal intensity for 0.5 nM concentration of the target DNA, (a) using the 
conjugates prepared by the old method and (b) using conjugates prepared by the new method. 
The variation in the signal shows the increase in sensitivity of the biosensor just by using 
different AuNP-DNA conjugates. The conjugates using the old method gave a signal intensity of 
16 (test line) as compared to the signal of 221 (test line) recorded for the conjugates prepared 
using the new method. The experimental parameters were kept identical for both assays. The 
bands on the image represents test line (left) and control line (right). The signals recorded using 
the portable strip reader are also shown. 
Figure 25: Shows the comparison between the signals for 0.5 nM DNA concentration using the 
Gold-Nanoparticle-DNA conjugates prepared by (a) the Old Method and (b) the New Method.  
 
The lateral flow biosensor with newly developed conjugates was also put to test with 
different concentrations of target DNA. As expected, the signal intensity on the biosensor 
increased with increasing amounts of target DNA. Figure 26 shows the image (visual) response 
captured via camera for varied target amounts. The control line appearance confirmed the 
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accurate function of the biosensor. The quantitative response was recorded and the resulting 
peaks were generated from the portable strip reader. The detection limit of 0.01 nM with a linear 
range of 0.01 nM – 100 nM was obtained for a 30 minute assay. This biosensor is capable of 
analyzing different concentrations of target DNA without any interference from the presence of 
other non-complementary DNA strands.  
 
Figure 26: Illustrates the biosensor response for different concentrations of target DNA and their 
respective signals obtained from the portable strip reader. The calibration curve for the intensity 
or signal obtained vs. the DNA concentration.  Inset shows the linear response obtained at lower 
concentrations ranging from 0.01 nM to 0.1 nM. 
 
The basis for this research was to make this biosensor more sensitive to small amounts of 
target DNA so that it can be used widely and for on-site detection or analysis. This biosensor, 
compared to work of Liu et al. (2009), is about 50 times more sensitive using simpler preparation 
techniques. If compared to other techniques used for detecting DNA samples, this biosensor is a 
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fast, easy and quite sensitive method. This procedure without amplification can provide good 
sensitivity for detecting 0.01 nM of target DNA in 100 µl of sample solution within half an hour, 
and a high reproducibility was achieved with a Relative Standard Deviation value of 4.08%. The 
major improvement done to this work compared to any other method of nucleotide detection was 
to the time and money required for diagnostics, as it does not require any kind of expensive 
instrumentation or reagents which could add to the cost of the biosensor. 
Interference from human serum was also tested on the lateral flow biosensor. DNA target 
samples spiked with human serum showed equivalent responses compared to target in buffered 
solution. The results obtained were plotted on a dot plot (Figure 27(a)), and showed linear with 
respect of log (concentration) response with increasing concentrations of target. 
The target DNA sequence selected was a part of human genomic DNA. A sample of 
human genomic DNA was also detected by the biosensor, but since the genomic DNA is a long, 
double-stranded sequence, it took relatively longer assay time of about 45 minutes. The lowest 
amount of genomic DNA that can be detected on the biosensor is 0.25 ng/ml (~7.69x10-15M). 
Figure 27(b) shows the calibration curve for different concentrations of signal intensity vs. 
genomic DNA. This promising biosensor showed great results for human genomic DNA 
detection, which implies that it can be used for real-world applications.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
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Figure 27: Shows calibration curve for (a) different concentrations of Target DNA spiked with 
10 µl of undiluted human serum for every 100 µl of sample solution and (b) different 
concentrations of human genomic DNA as a target. 
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4.7. Conclusion 
This work successfully developed a biosensor which is sensitive and fast for the detection 
of nucleic acid samples. This biosensor involved a conjugate preparation method which required 
less time and reagents as compared to the biosensor (DNAB) already introduced using the same 
principle of detection. Without the need for an amplification strategy, the technique provided a 
detection limit 50 times lower compared to the previously-known method. This fast, simple, 
reproducible, sensitive, low cost, and disposable biosensor based on sandwich hybridization 
immunoassay has a detection limit of 0.01 nM. The biosensor can also be used for real-sample 
detection in serum with a detection limit of 0.05 nM, and human genomic DNA with a detection 
limit of 0.25 ng/ml. The biosensor can be used for point of care and practical applications for 
DNA analysis.  
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CHAPTER 5. DETECTION OF C. TRACHOMATIS AND N. GONORRHOEAE 
This chapter reports a DNA-AuNP based lateral flow nucleic acid biosensor for the 
sensitive detection of multiple STI targets based on sandwich hybridization reaction. The 
accumulation of the AuNP conjugates on the test zones enabled visual detection of multiple 
nucleic acids simultaneously. This proof of concept is demonstrated with the simultaneous assay 
for the detection of DNA from Chlamydia trachomatis and Neisseria gonorrhoeae strain 
samples. This study provides a simple, rapid, specific and low cost approach for the detection of 
multiple targets in a sample without interference. The work also shows great potential and 
promise for parallel point-of-care (POC) diagnosis and clinical applications. 
5.1. Introduction 
In the United States, Chlamydia trachomatis is the most common bacterial STI. It is also 
a major cause of pelvic inflammatory disease (PID) that leads to infertility and ectopic 
pregnancy. There are estimated to be three million new cases recorded every year. CT is an 
obligate, intracellular gram-negative bacterium. Mostly found in young women and men, this 
infection, if left undetected or untreated, can cause inflammation and scarring in both male and 
female reproductive systems. The second most prevalent disease in the USA is infection by 
Neisseria gonorrhoeae. NG is a pathogen responsible for causing 87.5 million new infections 
worldwide every year. Although gonococcal infection can be treated with use of antibiotics, no 
vaccines are available. More importantly, NG has also been associated with the transmission of 
other sexually transmitted diseases, including human immunodeficiency virus (HIV) (Chen et al., 
2000; Jang et al., 1998; Pare et al., 1998). 
Current screening practices differ around the world. Culture analysis of swab specimens 
was considered the diagnostic gold standard traditionally. Improvements were made by 
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developing antigen detection tests, enzyme immunoassay and nucleic acid hybridization. Lately, 
amplified assays, ligase chain reaction (LCR), strand displacement and transcription mediated 
assays have been used. Although culture tests are 100% accurate, theydo not provide high 
sensitivity to the desired target. Non-culture methods also suffer from disadvantages like 
antibody cross reaction and false positives. Nucleic acid amplification tests (NAATs) have 
become very popular assay for both CT and NG. These assays amplify and detect nucleic acid 
sequences unique to either CT and/or NG. These assays offer high sensitivity and selectivity and 
do not require a viable micro-organism. They offer a lot of advantages including high 
performanceand reliability results without interference from specimens such as those contained 
in urine or swabs. Despite of the ease of the assay, the NAATs’ disadvantages are their cost, 
reduced performance in the presence of inhibitors and the need for sampling pre-treatment. 
5.2. Brief Literature Survey 
C. trachomatis and N. gonorrhoeae are of the two most prevalent bacterial sexually 
transmitted infections reported to the Center for Disease Control and Prevention (CDC), 
accounting for over 1.6 million reported infections in 2010 (Guaschino et al., 2000). The CDC 
estimates that these STIs have high rates of infection among female sex workers in developing 
countries, and cost the global health care system $1.5 billion annually (Castriciano et al., 2002). 
Since these infections, especially CT, are most often asymptomatic, the CDC recommends yearly 
screening in all sexually active women ages 16-25 years of age (Banoo et al., 2006). Traditional 
laboratory diagnosis of these infections is done by culture for N. gonorrhoeae and cell culture or 
antigen detection for C. trachomatis (Vasoo et al., 2009). Recently, NAATs have become widely 
accepted and are now recommended by the CDC as the test of choice; however, current NAATs 
are classified as high or moderate in complexity, and may take 1-2 days for results (Mills et al., 
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2010; Okele et al., 2011). Also, molecular amplification techniques have been demonstrated to 
have improved sensitivity compared to culturing (Babo et al., 1991; McKiernan et al., 2010) and 
other diagnostic assays for the detection of chlamydia infection in urine, endocervix (Boman et 
al., 1997), throat and urethral swabs (Maass et al., 1994), sputa (Quinn et al., 1994), broncho 
alveolar lavage fluids (Tong et al., 1993), and eye secretions (Toye et al., 1996). New assays and 
new platforms which provide results at the time of patient visits are urgently needed, since many 
patients do not return for their results when laboratory-based tests that require several days to 
complete are performed. For this reason, lateral flow immuno-chromatographic tests or Rapid-
Diagnostic-Tests (RDTs) provide emerging tools to screen infectious diseases even in resource-
limited settings or remote locations where conventional approaches (e.g. clinical examination, 
standard lab-tests and microscopy) are limited (Zhu et al., 2012).  
Today, with the achievements of nanotechnology, nanoparticle-based biosensors have 
aroused great interest, especially because nanoparticles can take advantage of signal 
amplification to achieve high sensitivity and selectivity for target analysis (Dong et al., 2013; Su 
et al., 2013; Zhang et al., 2013). A kind of lateral flow strip biosensor that combines 
nanoparticles with conventional immunoassay has attracted significant attention in biological 
analysis and clinical diagnosis in past years (Singer and Plotz, 1956; Zhang et al., 2006). Lateral 
flow strip biosensors are considered one of the most promising diagnostic technologies, owing to 
their simplicity, rapid analysis, low costs, high sensitivity and specificity (Zhang et al., 2006). In 
addition, they show less interference and more long-term stability over a wide range of climates 
(Cho et al., 2005).To date, several lateral flow strip biosensors have been developed to detect 
many objects such as DNA, mRNA, proteins (Mao et al., 2009; Xu et al., 2008), biological 
agents (Fisher et al., 2009; Liu et al., 2009; Nakasone et al., 2007; O'Keeffe et al., 2003; Xia et 
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al., 2009) and chemical contaminants (He et al., 2011; Li et al., 2007). Nevertheless, there are 
very few reports on multiplex DNA analysis using lateral flow strip biosensors. As a result, it is 
highly desirable to develop a facile, rapid and economical approach for the accurate detection of 
multiple DNA targets with a real-time application. 
Herein is reported a lateral flow nucleic acid biosensor (LFNAB) for specific and 
sensitive detection of multiple nucleic acid sequences simultaneously. Under optimal conditions 
the platform was also applied to the successful detection of DNA extracted from C. trachomatis 
and N. gonorrhoeae cell strains with PCR amplification. The amplified product of the two STIs 
was tested directly on the LFB-CT/NG for visual response without the need for sample 
processing and washing steps. The promising properties of the approach are reported in the 
following sections. 
5.3. Preparation of Chlamydia trachomatis and Neisseria gonorrhoeae Sample 
DNA from chlamydia and gonorrhoeae cultures were prepared by the Chelex method 
(Walsh et al., 1991). Mixtures of 50 ml of specimen and 200 ml of a 5% suspension of chelating 
resin (Chelex 100; Sigma, St. Louis, Mo.) in Tris HCl buffer (0.01 M, pH 8.0) were incubated at 
56 °C for 15 to 30 minutes. The chelating resin was held in suspension by continuous stirring 
with a magnetic bar while it was added to the specimens. After incubation, preparations were 
mixed gently and heated at 100 °C for 8 to 10 minutes. After being mixed again, preparations 
were stored at 270 °C. Immediately before testing, preparations were centrifuged for 30 seconds 
in a micro centrifuge and 10 ml of the supernatant was used for PCR. A three-plex Takara 
SpeedSTAR PCR mixture was made containing forward- and biotin-labeled reverse primers 
(Gaydos et al. 2000) for CT (400 nM) and NG (400 nM). 
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Primers used for C. trachomatis (CT) -Product (316bp) and N. gonorrhoeae (NG) -
Product (132bp): 
Forward (CT): 5`- GGCGATATTTGGGCATCCGAGTAACG -3` 
Reverse (CT): 5`- Biotin/-TCAAATCCAGCGGGTATTAACCGCCT -3` 
Forward (NG): 5`- CGGTTTCCGTGCGTTACGA -3` 
Reverse (NG): 5`- Biotin/-CTGGTTTCATCTGATTACTTTCCA -3` 
This mix was split into four different aliquots. To each aliquot, additional template was 
added:  
1. No additional template  
2. CT template 
3. NG template 
4. CT and NG template 
These mixes were then split into PCR tubes (four copies each) of 50 l each and were run 
in a commercial thermocycler (iCycler) with one cycle at 95 °C for1 minute and 40 cycles at 95 
°C for10 seconds and 55 °C for 30 seconds). The end product is a sequence with the 5’ end 
labeled with biotin on one of the strands of the double-stranded product. On denaturation of the 
product, two sequences are obtained with half of the single strands labeled with biotin.  
5.4. Preparation of Lateral Flow Strip for C. trachomatis and N. gonorrhoeae 
The following sequences were designed for Lateral Flow Biosensor. 
Oligonucleotides used for LFS-CT/NG were as follows: 
CT-Probe 1 (LFS-CT-Test Line):  5'-CCTTTACCCCACCAACTAGC-3'/Biotin/-3′  
CT-Probe 2 (LFS-CT-Conjugate):  5′-ThioMC6-D/CCAATCTCTCAATCCGCCTA-3′ 
NG-Probe 1 (LFS-NG-Test Line): 5'-ACTCGGAACAAATTGAATGC-3'/Biotin/-3′ 
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NG-Probe 2 (LFS-NG-Conjugate): 5′-ThioMC6-D/GCGTGAAAGTAGCAGGCGTA-3′ 
CT/NG Probe 3 (LFS-CT/NG-Control): 5′-Biotin/TACGCCTGCTACTTTCACGC-3’ 
The LFS-CT/NG was prepared according to the procedure described in Chapter 2 with 
slight modifications. Briefly, the sample application pad was saturated with a buffer (pH 8.0) 
containing 0.25% Triton X-100, 0.05 M Tris-HCl, 0.15 M NaCl for one hour; dried and soaked 
again in ½ SSC and 10% Tween for 10 minutes. The conjugate pad was dispensed with a desired 
volume of AuNP-DNA conjugate solution onto the glass fiber pad. Nitrocellulose membrane was 
dispensed with DNA probes (CT probe 1, NG probe 2 and CT/NG Probe 3) at different locations 
to form test zones and the control zone. To facilitate their immobilization on the nitrocellulose 
membrane, streptavidin was used to react with the biotin-labeled DNA probes to form the 
streptavidin-biotin DNA conjugates. Finally, the sample pad, conjugate pad, nitrocellulose 
membrane, and absorption pad were assembled on a plastic adhesive backing. Each part overlaps 
2 mm to ensure the solution is migrating through the strip during the assay. Strips with a 3 mm 
width were cut by using the Guillotine cutting module CM 4000. The sample pad of the cut strip 
was soaked in 0.025 mg/ml streptavidin and dried before use. 
5.5. Assay Procedure and Working Principle for CT/NG Assay 
The LFS-CT/NG was used to detect the PCR product, Figure 28. The sample was 
prepared by diluting PCR product in water followed by heat denature.  The sample (100µl) was 
heated in boiling water bath for 5 minutes and the LFS-CT/NG was inserted in the tube 
immediately following the heat step, such that the samples were still warm. The double-stranded 
PCR product denatures into single strands on heating and the streptavidin on the sample pad 
binds to the biotin-labeled product produced from the use of reverse biotin primer. The 
streptavidin allows the other complementary half of the PCR product to move along the 
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biosensor and hybridize to the DNA labeled on AuNPs. The conjugate-target complex migrates 
along the membrane and forms a sandwich complex with the probes on the test zones.  The 
excess conjugates form a double-stranded complex on the conjugate zone giving a red band at 
the end of the test run. The bands were visualized within 15 minutes as illustrated in Figure 29. 
For quantitative measurements, the strip was inserted into the strip reader DT1030, the optical 
intensities of the test lines and the control line were recorded simultaneously by using the 
“GoldBio strip reader” software. LFS-CT/NGs were stored at 4 °C until ready for use and were 
then brought to room temperature before applying samples. 
 
Figure 28: Typical analytical procedure to detect PCR-amplified DNA  with the LFS-CT/NG 
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Figure 29: Shows the detailed mechanism of working principle on the lateral flow biosensor 
upon application of the test sample. 
 
5.6. Optimizations of Different Parameters 
Various conditions were optimized during the development of an assay for the 
simultaneous detection of CT and NG. The first optimization was performed on the sample pad 
preparation. Since this work eliminates the use of running buffer, using water for testing instead, 
the sample pad was tested with components of running buffer to initiate more sensitive detection 
of samples. Figure 30 shows the signal response from the use of different buffers. The sample 
pad was soaked in the listed buffers for 30 minutes each. Testing was done with 5 µl PCR diluted 
to 100 µl using distilled water. The results indicated that the use of half diluted 20XSSC in 
combination with Tween-20 increased the signal response immensely without any false 
responses without target present. Therefore, 1/2SSC + 10% Tween was selected for additional 
treatment of the sample pad for 30 minutes. The soaking time was also optimized during the 
work. It was observed that soak time affected the response greatly under the sample working 
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conditions. Based on the results obtained in Figure 31, 10 minutes soaking time was identified as 
the best condition. Increasing time increased the signal, but the background noise increased as 
well. This led to false adsorption of conjugates on the nitrocellulose membrane. More 
optimizations were performed during the preparation of the LFS-CT/NG. Different types of 
nitrocellulose membrane were compared. Unlike the usual trend from previous projects, the 
membrane HFB24004 showed a lesser response compared to HFB18004 (Figure 32). It is 
hypothesized that since HFB24004 membrane forces solution to travel slowly through the 
membrane due to the pore size, this possibly results in the re-hybridization of the target strand to 
the complementary strand from the PCR product. The membrane that allows faster movement 
limits the re-hybridization of denatured PCR product, thereby permitting the target strand to 
move along the biosensor.  
Figure 30: Comparison of signal intensity vs type of buffer used to treat sample pad before test. 
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Figure 31: Amount of soak time for buffer vs signal intensity obtained for 5 µl product test. 
 
Figure 32: Graph comparing the signal response from the use of different types of nitrocellulose 
membrane during the preparation of LFS-CT/NG. 
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The amount of capture probe on the test zones was also optimized. 100 nmol liquid was 
dispensed multiple times on the test zone. Two test lines and one control line were dispensed 
with specific probes conjugated with streptavidin for immobilized dispensing. Figure 33 
compares the signal response from different number of cycles used. Higher concentration of test 
line cycles increased false signal in the presence of a non-complementary target. The LFS-
CT/NG was further improved by analyzing more conditions and optimizing the amount of 
conjugate loaded on the conjugate pad of the biosensor. As shown in Figure 34, best results were 
obtained with 2 dispensing cycles. The conjugate pad was prepared by mixing the two 
conjugates (AuNP-CT-DNA and AuNP-NG-DNA) in equal volumes followed by dispensing 
different number of times.  
Figure 33: Shows the difference in signal obtained with increasing concentration of Test Line 
amount dispensed on the LFS-CT/NG. 
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After the assembly of all components of the LFS-CT/NG, the biosensor was cut into 3 
mm wide pieces. Finally, on the edge of each sample pad, streptavidin solution was loaded with 
a pipette. 10 µl solution with different concentration of streptavidin was dropped and air dried. 
Figure 35 compared the response from different amounts of protein used per strip. Above 0.025 
mg/ml, there was not a significant increase in the signal response. Hence, 0.025 mg/ml was 
chosen as the optimum amount of streptavidin per strip. The LFS-CT/NG was stored at 4 °C 
until further use. 
Figure 34: Shows the response recorded with increase in concentration of AuNP-DNA 
conjugates mixtures dispensed on the LFS-CT/NG 
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Figure 35: Graph showing the amount of Streptavidin loaded on the sample pad after the 
assembly of LFS-CT/NG vs the signal obtained. 
 
5.7. Results and Discussion 
Upon completion of PCR for Chlamydia trachomatis and Neisseria gonorrhoeae, the 
amplified product was validated via gel electrophoresis. Figure 36 shows the gel image obtained 
after the samples were run on 3% agarose gel. The 50bp dsDNA ladder was run in the first lane 
to the left (lane 1) with a non-template control (lane 2), CT as template (lane 3), NG as template 
(lane 4) and CT+NG templates (lane 5). The position of the bands on the gel indicate that the 
samples (CT and NG) amplified as 316bp and 132bp products, respectively. Two bands were 
observed in lane 5 of the gel indicating that both templates were amplified without interference 
from each other. Smaller bands were observed at the bottom of all lanes indicating the presence 
of excess primers in the reaction mixture. The biosensor was tested in the presence of both/none 
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target products (Figure 37). The LFS (1) and (2) shows the control response in the presence of 
water (without target) validating the function of the biosensor. The LFS (3), (4) and (5) gives the 
response in the presence of 10 µl CT, 10 µl NG and 20 µl CT+NG, respectively. For quantitative 
measurements, intensities of the test zones were recorded with the portable strip reader. The 
reproducibility of the system was also confirmed by testing replicates of the diluted sample. 
Figure 38 shows the LFS-CT/NG image taken from a camera: the response from control (left) 
and four sample strips containing CT and NG PCR products diluted in water. Same 
concentration was tested for both targets but the difference in the intensity of two test lines is due 
to the difference in concentration of the PCR product, because of the length of the amplified 
product. The LFS-CT/NG successfully detected both targets simultaneously and without 
interference, sans any complex purification or separation procedures, suggesting potential 
clinical applications of the LFS-CT/NG in biomedical diagnosis. 
Figure 36: Illustrates the gel electrophoresis images containing (from left to right) Ladder, non-
template control (NTC), CT, NG and CT+NG PCR products. 
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Figure 37: Typical photo images of (1) and (2) represent control conditions with 10 µl NTC + 90 
µl Water. (3) and (4) show the presence of 10 µl NG target and CT target respectively. Strip (5) 
is the presence of both targets in equal volumes. Assay time: 20 minutes 
Figure 38: Typical images showing the reproducibility of the LFS-CT/NGs in presence of two 
targets. Strip on the extreme left is Control (NTC in water). 
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5.8. Conclusion 
In this work, the lateral flow biosensor was applied to the successful, simultaneous 
detection of Chlamydia trachomatis- and Neisseria gonorrhoeae-amplified DNA samples. 
Compared to traditional methods, this approach provides a simple, fast, selective and sensitive 
method for simultaneous detection of nucleic acids without any complex sample treatment nor 
expensive instrumentation. This study opens new opportunities for the detection of multiple 
nucleic acids in a sample matrix without interference. This work can be further improved by 
introducing more test zones for multiplex detection of different STIs. Due to its reliability and 
accuracy, this research’s biosensor shows great promise for the development of point of care 
detection of multiple STIs. 
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CHAPTER 6. DETECTION OF HPV-16 IN PATIENT SAMPLES 
This chapter discusses a lateral flow biosensor designed specifically to detect samples of 
Human Papilloma Virus Type 16 from patient samples. This work employed the biosensor 
discussed previously for the detection of multiple nucleic acids with high selectivity and 
sensitivity achieved by various experiments and optimizations. This section further details the 
work to create a successful platform for the detection HPV-16. 
6.1. Introduction 
HPV is amongst the most common STIs among people who are sexually active. The 
CDC estimated that 20 million people are infected with HPV-16 in the United States, and about 
5.5 million new cases are reported annually. The prevalence of HPV-16 is two times higher in 
women as compared to men. HPV-16 is the most common cause of cervical cancer. It also 
causes vulvar, anal, vaginal and penile cancers as well as other diseases which result in tumor 
formation (Cogliano et al., 2005). 
Human Papilloma viruses are small, double-stranded DNA viruses known to infect 
epithelium. To date, there are more than 100 types of HPV, classified by the genetic sequence of 
their outer capsid protein. Usually HPVs are known to cause common warts. But about 40 types 
infect the mucosal epithelium that is associated with cervical cancer. The non-oncogenic types, 
known as the low risk HPVs, can cause benign or low-grade cervical cell abnormalities, but the 
oncogenic (high risk) tend to be carcinogenic. High risk HPVs includes types 16, 18, 31, 33, 35, 
39, 45, 51, 52, 56, 58, 59, 68, 69, 73 and 82. These high risk HPVs are associated with about 
99% of cervical cancers. Of these, type 16 is found in 50% of these cancers (Kreimer et al., 
2005; D’Souza et al., 2007). For diagnostic purposes, HPV has not yet been isolated from 
cultures; the infection can be identified in clinical samples only. Currently, the only technique 
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approved by the Food and Drug Administration is the Hybrid Capture 2 (hc2) High-Risk HPV 
DNA Test used for clinical samples. But the widely-used approach does not offer specific 
results. This technique, which is only approved for use in women, can only provide positive or 
negative results, but does not differentiate the type of HPV present (Parkin 2006; Koutsky et al., 
1999; Weinstock et al., 2000). 
6.2. Brief Literature Survey 
The importance of detecting HPV and related biomarkers has led to development of 
several methods that can be employed to discriminate among lesions with high risk progression 
to cervical cancers. Since HPV cannot be propagated in tissue cultures, molecular biology 
techniques are used. The presence of HPV in cervical samples can be identified from 
morphological, clinical and serological findings (Villa & Denny, 2006; Porras et al., 2010).  
However, molecular biology techniques provide much better diagnosis for HPV. Nucleic acid 
hybridization assays use in situ hybridization, southern blotting and dot plot hybridization to 
detect HPV. As elaborated by Villa & Denny (2006), these techniques generate high quality 
information, but suffer from disadvantages such as low sensitivity and hence the need for large 
amounts of purified DNA. Signal amplification assays like Cervista HPV and Hybrid Capture 2 
provide quantitative results with high sensitivity to genotyping. Yet, these techniques fail to 
detect HPV types selectively and are not designed to genotype individual samples (Hwang & 
Shroyer, 2011; Wright & Schiffman, 2003; Frazer et al., 2011; Otero-Motta et al., 2001; Johnson 
et al., 2008; Einstein et al., 2010). Another commonly-used method involves nucleic acid 
amplification tests (NAATs). This method includes various techniques developed in recent years 
to increase the sensitivity of the detection along with multiplex analysis of samples. Some of the 
common NAAT methods include microarray analysis (Rahman et al., 1996), PapilloCheck for 
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multiplex assay (Pista et al., 2011; Bryant et al., 2011), PCR and real time PCR (Zaravinos et al., 
2009; Camargo et al., 2011; Coser et al., 2011; Carvalho et al., 2010; Nogara et al., 2012; Maver 
et al., 2010; Naqvi et al., 2004; Satiago et al., 2006), COBAS 4800 HPV test (Heideman et al., 
2011; Mateos et al., 2011), HPV genome sequencing (Sanger et al., 1992; Smith et al., 1986; Lee 
et al., 1992; Novais et al., 2011), CLART human papillomavirus 2 (Pista et al., 2011), INNO-
LiPA (Van Hamont et al., 2006; Sukasem et al., 2011; Lenselink et al., 2009; Schmeink et al., 
2011), Linear array (Dobec et al., 2011) and more. Some of these techniques provide specific 
results and determine high risk vs low risk HPVs. An additional risk with these tests: the signal 
response from HPV genotypes can contaminate the previously amplified material and lead to 
false positive responses. Since such techniques are expensive and fail to distinguish between 
HPV-16 and HPV-18—which are responsible for roughly 70% of cervical cancers (source)—this 
work introduces a lateral flow biosensor that can distinguish HPV-16 from HPV-18 PCR 
amplified product. The samples are applied on the biosensor and can be watched for the presence 
of a red band at the test zone indicating the presence of the target HPV-16. The following 
sections include the details of the work done to achieve this goal.  
6.3. Lateral Flow Biosensor 
The biosensor was developed on a backing layer with assembly of a sample pad, 
conjugate pad, nitrocellulose membrane and absorption pad. The detailed procedure is described 
in Chapter 2. A few modifications were made to the biosensor for its specificity to the HPV-16 
target. The sample pad was prepared by soaking the cellulose fiber membrane in a buffer (pH 
8.0) containing 0.25% Triton X-100, 0.05 M Tris-HCl, and 0.15 M NaCl for 1 hour at room 
temperature (RT). The dried sample pad was soaked in ½ SSC + 10% BSA solution for 10 
minutes. After drying completely, the sample pad was assembled with the rest of the components 
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of the biosensor. The conjugate pad was prepared by labeling a thio-labeled probe to 15 nm gold 
nanoparticles (AuNPs) using the dATP method introduced in Section 4.3. The sequence used for 
conjugation was 5'-/5ThioMC6-D/ATG ATC TGC AAC AAG ACA TAC ATC GAC CGG-3'. 
The Nitrocellulose membrane was designed with a test zone and a control zone. Two different 
streptavidin-biotin labeled DNA conjugates were prepared using 5'-/BIO-/TGT ACG CAC AAC 
CGA AGC GTA GAG TCA CAC-3' and 5'-/BIO-/CCG GTC GAT GTA TGT CTT GTT GCA 
GAT CAT-3' for the test and control zones respectively. The biosensor’s four components were 
assembled and cut in 3 mm wide pieces before testing as shown in Figure 39. The target DNA 
was extracted from cell lines and amplified with PCR for testing. The expected amplified 
product after the PCR was used to design the probe sequence for conjugates, control and test 
lines. 
Figure 39: The schematic representation of the lateral flow biosensor for the detection of HPV 16 
double stranded PCR product. 
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6.4. Sample Preparation 
Multiple cell lines were obtained from ATCC, Manassas, VA and cultured. The cell lines 
included ATCC CRL-1550 (Ca Ski), an adherent, epithelial cell line isolated from the cervix of a 
40 year-old female with epidomoid carcinoma. The CRL 1550, used as the target cell line, is 
reported to contain HPV-16 genome (about 600 copies per cell). Other cell lines included ATCC 
CCL-2 (HeLa) adherent, epithelial cell line isolated from a 31 year-old female’s cervix with 
adenocarcinoma. Since CCL 2 is reported to contain HPV-18 sequences, this cell line was used 
as a control cell line for selectivity against other high risk HPVs. Two more cell lines that were 
randomly selected were also used as controls: ATCC CCL-119 (CCRF-CEM) and ATCC HTB-
22 (MCF7) cell lines which do not contain any HPV sequences. The cells were cultured in 
conditions according to the procedures and protocols stated by ATCC.  
The whole cells from individual cultures were collected in PBS and different dilutions 
were used to extract total genomic DNA using the Quick-gDNA MicroPrep obtained from Zymo 
Research, CA. The total extracted DNA from each cell line was amplified for HPV-16 sequence. 
The primers selected (Forward Primer: 5’-CTGTCAAAAGCCACTGTGTCCTG-3’ Reverse 
Primer: 5’-GTGTGCCCATTAACAGGTCTTCCA-3’) allowed us to attain a double-stranded 
DNA sequence of about 400 base pairs. The resulting 400 bp was used as a target sequence for 
the lateral flow biosensor.  
The PCR amplification was carried out by using the standard protocol provided by Gaiffe 
et al. (2012) with slight modifications. The E6 HPV-16 gene was amplified after a hot reaction 
started at 94 °C for 5 minutes. The reaction was amplified for 35 cycles for 30 seconds at 94°C, 
30 seconds at annealing temperature (52°C) and 20 seconds at 72°C followed by a 5 minute 
extension at 72°C.  The amplified product was run on a 3% agarose gel for confirmation of the 
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desired product. For testing the sample on the lateral flow biosensor, the PCR product was 
denatured by heating the mixture in boiling water bath for 5 minutes and the biosensor was 
inserted in the 1.5 ml micro-centrifuge tube containing the sample solution to be tested (Figure 
40). The biosensor was added immediately to avoid cooling of the sample. The lateral flow 
biosensor was observed after 20 minutes for the appearance of one or two red bands on the 
nitrocellulose membrane. The intensity of the red bands was quantitatively measured using the 
portable strip reader. 
 
Figure 40: Shows the stepwise procedure for testing HPV-16 extracted from cell samples on a 
lateral flow biosensor. 
 
6.5. Optimizations of Different Parameters 
During the development of a biosensor for specific detection of HPV-16, various factors 
were considered and optimized for best results. The following experiments allowed us to 
maximize the signal response from the target cell line and minimize the background or control 
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signal from buffer or other cell lines. Figure 41 compares the use of different nitrocellulose 
membranes employed in the preparation of the lateral flow biosensor. Use of 3 minute 
(HFB18004) type showed higher signal response for target solution compared to the 4 minute 
nitrocellulose membrane. It was reasoned that the longer time on the membrane was thought to 
cool the sample solution, hence re-hybridizing the denatured strands from the PCR product. The 
amount of streptavidin-biotin labeled DNA probes dispensed on the nitrocellulose membrane 
was also altered during this work. Figure 42 shows the number of dispensing cycles using Biojet 
3000 for both test and control lines. The bars represent the signal response from the target 
solution in presence of increasing amount of test line probe. The test line dispensed twice with 
DNA probes showed the maximum signal intensity in the presence of target. Higher 
concentrations increased the response but the response from control cell lines increased as well, 
giving false positives. The optimum amount of two dispensation cycles was chosen to prepare 
the strips. 
Figure 41: Shows the comparison of different nitrocellulose membrane used in the Lateral Flow 
Biosensor preparation. 
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Figure 42: Bar graph showing the comparison between the signal intensity obtained at the test 
zone with increasing concentration of test line probe. 
 
Other optimizations included the type of buffer used to soak the sample pad and the time 
of the soak. This was done to replace the use of running buffer in testing sample. The elimination 
of running buffer allows a researcher to test the amplified product directly without any dilutions 
or sample treatments. Figure 43 compares the signal obtained from the use of different buffers 
soaked for 30 minutes on the sample pad. The signal intensity was improved when the soaking 
time for the buffer was reduced to 10 minutes as shown in Figure 44. These results conclude that 
presence of SSC buffer on the sample pad increased the hybridization efficiency immensely.  
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Figure 43: Bar graph comparing the signal response on the lateral flow device prepared with 
sample pad soaked in buffer for varying times. 
Figure 44: The response recorded from the use of different buffer components for Sample Pad 
vs. the signal intensity at the test zone. 
  
85 
 
As expected, BSA increased the sensitivity of the system by increasing the signal 
response compared to the use of Tween. Other buffer types showed no significant response. The 
amount of time the buffer was soaked on sample pad affected the signal intensity greatly. Even 
with the use of the optimum buffer type, if the soaking time was over 10 minutes there was a 
substantial decrease in the signal intensity as the concentration became too high, which affected 
the movement of the solution on the strip. It was observed that for higher soaking time the 
sample solution did not even move past the conjugate pad, hence even a control line was not 
observed. This led to the protocol of 10 minute soak time for a pre-treated sample pad.  
Optimizations were also performed for the amount of conjugate dispensed onto the 
conjugate pad. Each cycle of dispensation added more conjugates, increasing the concentration 
of AuNPs labeled with DNA probes. It was expected that increased amounts of AuNP-DNA 
would increase the signal intensity at the test line and the excess conjugate would hybridize at 
the control zone. As illustrated in Figure 45, after three dispensing cycles, there was not a 
significant signal increase observed for the test line. Therefore, three cycles for AuNP-DNA 
conjugates were dispensed on the conjugate pad for assembly onto the lateral flow biosensor.  
Figure 45: Compares the response on lateral flow biosensor prepared with different number of 
dispensing cycles for AuNP-DNA conjugates. 
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6.6. Results and Discussion 
After optimizations of different parameters, the samples were amplified and run on an 
agarose gel to confirm the product formation before testing on the lateral flow biosensor. This 
chapter includes different experiments and tests performed to successfully detect HPV-16 
without interference from other high risk HPVs.  
Significant experiments were conducted to increase the concentration of the amplified 
product after PCR to increase the sensitivity of the system. The PCR conditions were altered to 
increase the amount of target DNA. It was evident that the use of primers in equal concentrations 
would give a double-stranded product of 400 base pairs in length. The amplified product was 
confirmed by running samples on a 3% agarose gel. Figure 46(a) shows the amount of dsDNA 
product after PCR. In the gel image, lane 1 and lane 6 contained 10 µl solution of 100bp ladder. 
Lane 2 was run with 10 µl PCR amplified product from the genomic DNA of HPV-16 (sample 
target). Lane 3, 4 and 5 were control lanes containing 10 µl PCR product amplified using 
genomic DNA from CCL-2 (HPV-18), CCL-119 (CCRF-CEM) and HTB-22 (MCF-7) 
respectively. It was observed that no product was formed in control cell lines. The product seen 
in lane 2 specific for CRL-1550 (target cell line) was obtained corresponding to the 400 bp band 
of the ladder, confirming the desired amplification. Figure 46(b) shows a gel image of a 3% 
agarose gel run with samples obtained after a PCR using altered working conditions. The 
samples for amplification were run with varying concentrations of primers. The forward and 
reverse primers had a final concentration of 0.25 µM and 0.05 µM respectively in the mixture 
before run. The use of reverse primer in smaller amounts led to increased formation of single-
stranded DNA in the product. The presence of increased ssDNA in the final product was 
expected to increase the response on the lateral flow biosensor because the sequence of the 
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ssDNA was complementary to the chosen probes, incorporated on the biosensor for the specific 
detection of HPV-16. In the gel image, Lane 1 contains 100bp ladder (15 µl), Lane 2, 3, 4 and 5 
contains 10 µl PCR amplified product obtained after amplification of genomic DNA obtained 
from HPV-16, HPV-18, CCRF-CEM and MCF-7 respectively. Lane 2 showed two bands for the 
target cell line, HPV-16, as expected. The band at 400bp position corresponding to the ladder is 
the dsDNA product formed from the use of two primers specific for the target. The band at 
approximate position of 225bp was believed to be the band formed through the presence of 
excess forward primer in the PCR mixture. To confirm the validity of this hypothesis, the two 
samples obtained from two PCR runs were tested on the later flow biosensor. The results 
obtained from the sample run in gel (B) were better than product obtained from the use of 
primers in equal concentrations.  
The PCR product obtained from the use of primers with varying concentrations of both 
primers was thereby used to perform further experiments to detect HPV-16 samples on strips. 
Figure 47 shows the image captured from a camera after the test completion. Different samples 
obtained after PCR were diluted ten times using distilled water and tested on the lateral flow 
biosensor. Strip A contained only water; therefore, only one red band was observed in both strips 
(duplicates). The band observed corresponds to the control zone on the membrane, verifying the 
proper function of the biosensor. Strips B, C and D were tested with PCR product from control 
cell lines. Since the PCR mixture contained primers to amplify a specific region of the HPV-16 
capsid genome, there was no amplification for control cell lines, and no response was observed 
on the test zone for the three. Two red bands were observed in Strip E. The band at this strip’s 
test zone indicated the presence of desired target DNA obtained after amplification through PCR. 
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This showed that the biosensor is specific only to HPV-16, and can distinguish between other 
cell lines, including that with HPV-18. 
Figure 46: Gel image after running 10µl of PCR amplified product on a 3% agarose gel. (A) 
Shows the products obtained after PCR run from the use of Forward and Reverse Primers in 
equal concentrations. (B) Shows the products from differing amounts of the two primers. Each 
image corresponds to Lane 1 (and/or Lane 6): Ladder, Lane 2: HPV 16, Lane 3: HPV 18, Lane 4: 
CCRF-CEM and Lane 5: MCF-7. 
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Figure 47: Shows the image response obtained on the lateral flow biosensor after completion of a 
test. (A) 100 µl water + 0µl PCR Product, (B) 90 µl water + 10 µl PCR Product from MCF-7, 
(C) 90 µl water + 10 µl PCR Product from CCRF-CEM, (D) 90 µl water + 10 µl PCR Product 
from HPV-18 and (E) 90 µl water + 10 µl PCR Product from HPV-16 were tested after heat 
denature in boiling water. 
 
Another experiment was performed to evaluate the sensitivity of the biosensor. About 1 
million cells were isolated from each cell line. The whole cells were subjected to serial dilutions 
corresponding to different numbers of cells. Each sample constituting a different number of cells 
was used to isolate total genomic DNA. The isolated DNA was then used as a template for PCR. 
The amplified products from each cell line were run on an agarose gel to visualize presence of 
any bands that would indicate amplification. No bands were obtained for control cell lines for 
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any number of cells. Amplification was only expected in the target cell line (HPV-16), which 
showed bands on a 3% agarose gel. Figure 48 shows the gel image with the bands obtained after 
PCR amplification of HPV-16 genomic DNA. The image also shows the base pair position for 
the ladder used. The PCR completion resulted in two bands as expected because of the use of 
primers with different starting concentrations.  
Figure 48: Gel Image showing the PCR product upon amplification. Lane 1 to 9 corresponds to 
different number of HPV-16 cells used. Lanes represent PCR product diluted to correspond with 
100000, 10000, 1000, 100, 10, 1, 0.1, 0.01 and 0.001 cells respectively 
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The gel image response indicates that the band intensity decreased corresponding to the 
number of cells used for the extraction of genomic DNA, which henceforth were used as 
template for PCR amplification. The amplified product (approximately 100 µl) was also tested 
directly on the biosensor without dilutions or treatments. The amplified product was heat 
denatured and biosensor was added to the tube. Signal was obtained after 30 minutes. Figure 49 
shows the image captured using a camera after test completion. Three strips were tested for 
control only. Water was used as the sample solution without any PCR product. Two lines are 
observed for strips 1 to 9 corresponding to test and control line. The varying intensity of the test 
line was the result from the use of different amounts of amplified product. Lane 1 through 9 
parallels the PCR product. Serial dilutions were made of the PCR product to correspond to 
100000, 10000, 1000, 100, 10, 1, 0.1, 0.01 and 0.001 cells respectively.  
Figure 49: Image showing the biosensor after completion of a test. Water only strips contained 
no PCR product. Strips 1 to 9 were tested with 100 µl of PCR product obtained from decreasing 
number of cells’ genomic DNA. 
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The lateral flow biosensor was also tested for real-time application for HPV-16. Clinical 
samples were obtained from Dicarta, CA, containing positive cervical swab samples of people 
infected with HPV-16. The five samples were comprised of one negative and four positive 
samples for HPV-16. Each swab was centrifuged down and used for extraction of genomic DNA. 
The extracted product was used a template for PCR. The amplified dsDNA was denatured and 
tested on the lateral flow biosensor. Figure 50 shows the results obtained from the clinical 
samples captured via a camera. Strip A showed no response for test line, whereas strips B 
through E showed varied response on both test and control zones, confirming that A was the 
negative sample and B through E were samples positive for HPV-16.  
Figure 50: Real sample detection of negative (A) and positive (B-E) for HPV-16 in cervical 
swab. 
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6.7. Conclusion 
This work successfully developed a platform for the detection of HPV-16 in patient 
samples. Clinical cervix swabs were obtained, and DNA extracted from the sample was 
amplified via PCR. The amplified product was used to design complementary probes to capture 
the target for detection. The heat-denatured product was directly applied on the lateral flow 
biosensor to deliver a visual response within 30 minutes. The biosensor designed herein is 
capable of successfully differentiating HPV-16 from other cell lines, including high risk HPV-
18. This effort provides a sensitive approach to identify HPV in real samples, and demonstrate 
the biosensor’s capability to be used as a point of care diagnostic tool.  
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CHAPTER 7. SUMMARY 
DNA detection is of crucial importance in the field of point of care diagnostics. The 
Lateral Flow Biosensor developed in this work offered great sensitivity and selectivity against a 
wide range of nucleic acid targets. Short oligonucleotides specific to diseases or infections can 
be easily detected via the lateral flow platform introduced in this dissertation. The simultaneous 
and sequence-specific detection was achieved by introducing gold nanoparticles (AuNPs) 
functionalized with short oligonucleotides specific to target nucleic acids. DNA hybridization 
reactions between the target and AuNPs labeled with oligonucleotides were captured on different 
test zones of the biosensor designed specifically for individual targets. This sensitive approach 
provided visual results within 20 minutes and quantitative responses were obtained via portable 
strip reader in 30 minutes. This work allowed the successful identification of specific single-
stranded nucleic acid targets of about 40-60 bases in length from a mixture of non-
complementary sequences and other analytes.  
Despite the low detection limit of 0.5 nanomolar for each target detected simultaneously, 
the biosensor needed more improvements to increase sensitivity to allow for its use in real-
sample detection. It was proposed that altering the methods used in the preparation of the 
biosensor might improve the quality of the detection method. A new approach was employed for 
the conjugation of oligonucleotides on AuNPs that used dATP (deoxyadenosine triphosphate) as 
a surface blocker. The new preparation method allowed easy exchange of dATP with thio-
modified DNA at high temperatures. The 3 hour incubation created stable AuNPs functionalized 
with a high number of DNA on the surface. The new preparation method was applied to the 
detection of nucleic acids and, upon comparison with old methods of conjugate preparation, 
lowered the detection limit to 0.01 nanomolar. Real-sample analysis was successfully performed 
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using human genomic DNA with a detection limit of 0.25 ng/ml (~7.69*10-15 M).  Direct 
detection of human genomic DNA at varying concentration proved the potential of the biosensor 
for its use in point of care diagnostic applications.  
The sensitive approach developed in this work was put to test for the detection of other 
targets related to sexually transmitted infections. The work was improved by simplifying the test 
procedure for selective and sensitive detection of DNA isolated from STIs. The biosensor was 
modified to allow direct detection of samples without the need for buffers or instrumentation for 
analysis of the response. A test solution of single-stranded nucleic acid can be applied directly to 
the biosensor for a visual response within 20 minutes. Since the target concentration in DNA 
isolated from STIs was very low, the nucleic acids to be detected were amplified using PCR. 
Since PCR provided a high increase in the number of target copies, a successful detection 
platform was established that selectively detected STIs from a sample mixture. The biosensor 
technology was also applied to the detection of HPV16 DNA from patient samples obtained from 
clinics. Various cell lines (HeLa, CaSki etc.) were used to isolate DNA and amplified target was 
directly detected on the lateral flow biosensor.  
Due to the low copy number of target DNA in CaSki cells, the biosensor was unable to 
detect the target sequence directly without amplification. Since the biosensor developed in this 
research can distinguish between small oligonucleotides, STIs, and even allow for specific 
detection of HPV-16 without interference from other HPV high risk types (e.g. HPV-18), it was 
concluded that further work in the field of amplification for the biosensor can allow us to build a 
platform to diagnose samples with yet more simplicity and sensitivity.  
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